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ABSTRACT
PIVOTAL ROLE OF INTERLEUKIN-10 ON MICRORNA-155 EXPRESSION IN
REGULATION OF THE MONOCYTE RESPONSE IN HYPOTHERMIA

Adrian Theophil Billeter
July 26,2012

This project investigated the effect of hypothermia on the monocyte
response with the goal of understanding, which intracellular processes are
affected by hypothermia leading to differences in cytokine secretion. A better
understanding of the effects of hypothermia on the regulation of monocyte
responses would allow targeted interventions and may reduce complications and
death in hypothermic surgical patients. We found the following results:
1. The three major pro-inflammatory signaling pathways, Nuclear Factor

KI3,

p38 and c-Jun N-terminal-Kinase (JNK) of the Mitogen Activated Protein
Kinases pathway, have increased and prolonged activation with
hypothermia (32°C). The extracellular signal-related kinase (Erk) pathway
shows increased activation at 15 minutes at 39°C.

v

2. The prolonged and increased activation of the pro-inflammatory signaling
pathways results in a prolonged and increased expression of TNF-a
messenger RNA (mRNA) and protein and microRNA-155 at 32°C.
3. Increased activation of Erk at 39°C leads to induction of Interleukin-1 0
mRNA and production of IL-10 protein.
4. The high IL-10 protein levels at 39°C result in suppression of the
microRNA-155 expression, whereas the lack of IL-10 at 32°C prolongs
microRNA-155 expression.
5. The increased and prolonged expression of microRNA-155 results in
increased and prolonged TNF-a production at 32°C.

The findings of our research demonstrate the importance of regulatory
feedback loops in order to achieve a balanced immune response. The lack of
the inhibitory IL-10 at 32°C results in a prolonged pro-inflammatory response,
which may have detrimental effects on host defense with a subsequently
increased susceptibility to infections and organ dysfunction. The improved
understanding of the intracellular mechanisms involved in the regulation of the
monocyte response may result in targeted interventions to ameliorate the
detrimental effects of hypothermia.
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CHAPTER 1
GENERAL INTRODUCTION
Hypothermia is a strong independent predictor of complications and
mortality in surgical patients (1-10). Hypothermic trauma patients are at an
especially high risk for death (1,4-6,8,9). In severely injured patients,
hypothermia very often occurs together with acidosis and coagulopathy in
patients with hemorrhagic shock, the so-called "triad of death". The detrimental
effects of hypothermia have also been described in elective surgery with
increased rates of surgical site infections and increased blood loss
(2,3,7,11 ).Therefore, prevention of hypothermia, but especially aggressive rewarming in already hypothermic patients are important steps during every
surgical procedure and an integral part of the care of the injured patient (12-14).
The reason for the increased rate of surgical site infection and multiple
organ dysfunction (MODS) in hypothermic patients is largely unclear. Early work
demonstrated decreased formation of Reactive Oxygen Species (ROS) in
phagocytes of hypothermic patients. These results have been reproduced in
cooled blood of healthy volunteers (15,16). Other investigators found impaired
dendritic cell function in hypothermia, a cell with a pivotal role in the initiation of
the immune response (17). Differences in pro- and anti-inflammatory cytokine
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production between hypo- and normothermic conditions have been reported by
several groups, although some of these results are contradictory (18-22).
As of yet, the intracellular mechanisms leading to these observed
differences in cytokine production and cell function have not been thoroughly
investigated. It has been shown that hypothermia affects activation of central
inflammatory signaling pathways and that the gene expression of monocytic cell
lines, when were exposed to hypothermia, are profoundly dysregulated (19,2325). The interactions of the different activation of signaling pathways, gene
expression and other regulators of cell function such as microRNAs have not
been investigated.
The purpose of this work is to investigate which mechanisms lead to the
observed differences in cytokine secretion, in order to understand the regulation
of the monocyte immune response and, identify areas for potential therapeutic
interventions that may restore monocyte function.
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CHAPTER II
BACKGROUND
CLiNICLAL IMPORTANCE OF HYPOTHERMIA
The care of the surgical patient has progressed significantly over the last
century. The mortality of elective colon resection continuously decreased from
above 30% in 1914 to 1.5% currently (26,27). The reasons for this development
are manifold. The introduction of blood banks in the 1940's allowed surgeons to
operate on more patients and reduced the immediate post-operative mortality
(26). Prophylactic antibiotics use decreased surgical site infections (SSI)
subsequently reducing postoperative morbidity and mortality (28). Several
decades later, among many other interventions, adequate blood glucose control
was found to further reduce morbidity and mortality in surgical patients (29).
In order to assure safe and high quality surgical care throughout the
United States of America, the Surgical Care Improvement Project (SCIP) was
started with the goal of reducing complications and mortality of surgical patients.
Practice guidelines based on clinical trials were issued, which aim to improve
surgical safety and outcome. SCIP includes one process measure to reduce
cardiac complications, two process measures with regard to venous
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thromboembolism prophylaxis and seven process measures, which aim to
reduce surgical site
infection. Three of these seven measures deal with the appropriate choice, timely
administration and discontinuation of antibiotics within 24 hours post operatively.
The next three measures recommend appropriate hair removal, blood glucose
control and early removal of urinary catheters. The last SCIP measure aiming to
reduce surgical site infection is prevention of hypothermia. In contrast to
hypothermia, fever is believed to be beneficial for host defense. Kluger
demonstrated that fever is protective and that infected, ectothermic animals
increase their body temperature by exposing themselves to higher environmental
temperatures (30).
Hypothermia has been shown to increase wound infections in several
studies. The early work of Kurz et al. in 1996 demonstrated in a prospective and
randomized study that prevention of hypothermia reduces surgical site infections
(7). Besides reduction in wound infections, the authors also found a significantly
shorter time to food intake and a shortened length of hospital stay. These results
were confirmed by other groups. Flores-Maldonado found a six-fold increased
risk for wound infections in patients who became hypothermic during an elective
cholecystectomy (31). Seamon et al. also found increased wound infections in
trauma patients who became hypothermic during the initial operations, but were
not hypothermic at admission (4). In non-abdominal operations, hypothermia was
also found to increase blood loss and post-operative complications (32). Taking
these results a step further, Melling et al. demonstrated that warming of the site
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of the surgical incision or the whole patient before the operation, is able to reduce
the rate of surgical site infections (33).
Other studies challenged these results. Barone et aL could not find an
association between intraoperative hypothermia and wound infection in a
retrospective chart review (34). Lehtinen et al. and Smith et al. found no impact
of hypothermia on wound infection (35,36). Walz et al. even found a decrease in
wound infection in hypothermic patients, although the body temperature
difference was clinically not significant between the two groups (37).
In addition to the effect on the rate of operative wound infections,
hypothermia has also been associated with increased mortality. The main body
of this evidence originates from the trauma literature. Several publications found
a highly significant association between admission temperature and death (1,5,810,14). Beilman et al. found increased rates of organ failure but no impact on
mortality in hypothermic trauma patients (6). Two recent studies challenge the
direct effect of hypothermia on mortality. The authors of these studies propose
that hypothermia is a marker for severely injured patients rather than the cause
for the increased mortality (38,39). Of note, Mahid et al. found that hypothermia
in elective surgical patients is associated with a four-fold increase in mortality (2).
Importantly, the cause of death in hypothermic patient is not necessarily related
to infectious complications. Frank et al. found a significant increase in cardiac
morbidity in elective surgical patients with perioperative hypothermia (40).
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In septic patients, the development of hypothermia is very detrimental or
at least a sign of failing host defenses. Septic patients, which present with or
develop hypothermia, have a two-fold increase in mortality compared to febrile
septic patients (41-44). Furthermore, a very recent study proposes that the use of
anti-pyretic agents in septic patients may be detrimental and should be avoided
(45). These results suggest that fever has a beneficial effect on the host defense
and the lack of fever, especially when hypothermia develops, is a marker of the
failure of host defense.
In summary, the majority of the available literature demonstrates that
hypothermia has detrimental effects on outcomes in both surgical and medical
patients. In surgical patients, hypothermia often occurs during or even before the
operation and subsequently leads to increased rates of complications and death.
In medical patients with sepsis, hypothermia is more a consequence of a failure
of the immune system to mount an appropriate response and, consequently, is
strongly associated with death in these patients.
The mechanisms by which the body temperature is regulated and the
roles of cytokines in this process are very complex and not very well understood.
Interleukin-1 (IL-1) and IL-6 have mainly pro-pyretic functions, whereas Tumor
Necrosis Factor-a (TNF-a) is believed to induce hypothermia (46). The
organization of the immune response, the involved cells, their secreted cytokines
as well as the impact of hypothermia on these processes will be discussed next.
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OVERVIEW OF THE IMMUNE RESPONSE
The purpose of the immune system is to defend the host against invading
pathogens such as bacteria, fungi, and viruses. It is also responsible for removal
and clearing of dead cells and plays an important role in inducing repair
mechanisms after injury (47). While executing all these tasks, the immune
system must not attack healthy host cells and the development of autoimmunity
must be avoided. For this purpose, the immune system evolved in two different
systems, which are separated into the innate system, which is considered the
older of these two systems, and the adaptive system. The innate system is the
primary defense and reacts immediately, but not specific to any kind of trauma or
infection with a reproducible response. This type of immune response can be
found in all vertebrates as well as some plants, fungi and primitive multicellular
organisms (47). The adaptive system mounts a much slower response, it takes
several days to react, but is much more specific and targeted than the innate
system. Once the adaptive system has been exposed to a certain pathogen, the
second exposure to this same pathogen results in an immediate, stronger
response, often preventing the actual infection. However, these two systems
cannot be separated as clearly as described here and there are multiple
important interactions between cells of both systems. In fact, the adaptive system
relies on activation signals from the innate system. We focus our studies on the
monocyte/macrophage, a cell of the innate immune system, which is the principle
activator of the adaptive system.
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The innate immune system consists of two major components: passive
defense mechanisms such as epithelial barrier, mucous fluids and secreted
proteins, which inhibit the growth of pathogens. The second and active defense
system consists of several different types of immune cells. The largest numbers
of these innate immune cells are granulocytes of which the majority are
neutrophil granulocytes (neutrophils). The main role of these neutrophils is the
phagocytosis and destruction of pathogens, mainly bacteria and fungi. The
eosinophil granulocytes are involved in the destruction of parasites, whereas the
role of the basophil neutrophils is not very clear. Mast cells are found in tissues
and the abdominal cavity. These cells are loaded with vesicles filled with
histamine and other vasoactive and immune-active substances, which can be
released via an antibody-dependent pathway or by direct activation of the mast
cell. Mast cells have been implicated in development of hypothermia in
endotoxemic shock (48).

Monocytes, Macrophages, Dendritic Cells and Their Relationship
Monocytes, macrophages and dendritic cells are important cells of the
innate immune system. These three cell types are related: the macrophages and
dendritic cells originate from the monocytes, which is the precursor found in
blood and bone marrow (49,50). Macrophages and dendritic cells are found in all
tissues. Tissue macrophages have different names based on the tissue they
were first described such as Kupffer cells for the liver or Langerhans cell for the
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skin because they were described in histologic preparations before their role and
common origin had been elucidated. Macrophages and dendritic cells patrol the
tissue in order to detect invading pathogens, but also to remove necrotic cell
debris. After tissue injury or the detection of pathogens, macrophages release a
host of cytokines and chemokines leading to the attraction of neutrophils and
other immune cells, which act to eliminate the infection and repair of the tissue
injury (51). Macrophages and especially dendritic cells have another, very
important role which is to induce the adaptive immune response. Macrophages
present antigens with the Major Histocompatibility Complex II (MHC II) from the
phagocytized pathogen to T - and 8-cells of the adaptive system resulting in the
induction of the adaptive immune response. This function of antigen-presentation
is an essential role of these cells. One of the major MHC II receptors is HLA-OR
(Human Leukocyte Antigen-DR). Expression of HLA-OR on monocytes has been
demonstrated to be a reliable marker for outcome after trauma and burns (5259). Low expression of HLA-OR and especially the lack of up-regulation of HLADR after ex-vivo stimulation with LPS, correlates with increased complications
and death. The restoration of the antigen presenting capability of peripheral
blood monocytes can be achieved by administration of immune-modulatory drugs
such as Interferon-y (IFN-y) or the Granulocyte-macrophage colony-stimulating
factor (GM-CSF) (56,57,60,61). However, thus far a clinically relevant
improvement in survival rates parallel with increased HLA-OR expression has not
been demonstrated. Hypothermia reduced HLA-OR expression whereas fever
increases HLA-OR (62,63).
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At least two different subtypes of peripheral blood monocytes have been
described. The "classical" monocyte expresses a high level of CD14, an essential
surface receptor for recognition of LPS, a medium level of HLA-DR and no CD16
(CD14++HLA-DR+CD16-) (49,64-67). Over 80% of the peripheral blood
monocytes are "classical" monocytes; the remaining are so-called "inflammatory"
monocytes. In addition, an intermediate between the "classic" and "inflammatory"
monocyte may exist. The "inflammatory" monocyte expresses a low level of
CD14 but high levels of HLA-DR and CD16 (CD14+HLA-DR++CD16+). These
"inflammatory" monocytes produce high levels of TNF-a, but low or no IL-10
(64,67,68). In addition, stimulation of T-cells is stronger and more efficient. In
inflammatory states, a shift to a higher percentage of "inflammatory" monocytes
can be observed (64,69). It is currently believed that these "inflammatory"
monocytes develop into strongly pro-inflammatory dendritic cells, the so-called
"tip-DCs" (50,70). In addition to the differences in cytokine secretion,
"inflammatory" monocytes (CD16+) are able to leave but also re-enter the blood
stream or lymphoid tissue, whereas "classic" monocytes are only able to leave
the blood stream but cannot re-enter (50,65,67,70,71). These "classical"
monocytes replenish the pool of tissue macrophages and support the tissue
macrophages during infections.
In summary, monocytes are the precursor of the macrophages and
dendritic cells and play an important role in the immune response. Clinical
evidence suggests that the dysfunction of the monocyte/macrophage systems is
a major contributor for infectious complications such as sepsis. We and others
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believe that hypothermia affects the monocyte function, as indicated by reduced
HLA-DR expression and changes in cytokine secretion, and this impaired
function contributes to the higher risk of infectious complications in hypothermic
patients (17).

Sequence of the Immune Response
An outline of the initial phase of the immune response and the role of the
monocyte/macrophage is shown in Figure 1. An infection with bacteria leads to
activation of monocytes or macro phages by two routes. Monocytes recognize
pathogen associated molecular patterns (PAMPs) such as components of cell
walls of bacteria such as Lipopolysaccharide (LPS) from gram-negative bacteria
or Lipoteichoic-acid from gram-positive bacteria (72). In addition, the infection
leads also to tissue destruction, which results in the release of endogenous
proteins from these cells such as heat shock proteins (HSP) or the High-Mobility
Group Protein 81 (HMG81), which are referred to as alarmins (73-76). PAMPs
and alarm ins together are referred to as danger associated molecular patterns
(DAMPs) (77,78). The bacterial components as well as the endogenous proteins
are recognized by a variety of receptors on monocytes. These receptors
recognizing certain distinct patterns of pathogens are termed Pathogen
Recognition Receptors (PRR's). The activation of these PRR's results in the
activation of intracellular signaling pathways and subsequent secretion of
cytokines and chemokines (51,79,80). The cytokines activate other immune cells
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in the same tissue but also in the whole body if they are released systemically.
Furthermore, cytokines such as TNF-a, IL-6 and 11-113 are responsible for the
systemic effects of an infection such as fever, increased cardiac output,
vasodilatation and the release of more immune cells from the bone marrow (72).
The chemokines attract other immune cells to the site of infection. The main
incoming cells are neutrophils, which phagocytize and destroy the pathogens.
After clearance of the bacteria, lipid-mediators such as Protectins and Resolvins
are secreted attracting more monocytes/macrophages to the site of infection.
These lipid mediators increase the phagocytic activity of the
monocytes/macrophages without stimulating the release of pro-inflammatory
cytokines (resolution of inflammation) (81,82). The non-inflammatory
macrophages remove the debris and remainders of the apoptotic or necrotic
neutrophils. Furthermore, tissue repair is stimulated and fibroblasts induce the
healing of the wound and usually form a scar which matures over time.

Role of Cytokines in the Immune Response
The secreted cytokines serve as messengers of the immune system and
coordinate the local response by attraction of different leukocyte subtypes, as
well as by inducing a whole body response, which aims to prepare the host to
fight the infection in the best possible way (83-86). The attraction of additional
leukocytes is supported by the local secretion of chemokines. Leukocytes follow
a gradient of chemokines to the site of infection and are activated by cytokines in
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the same environment. In addition, the cytokines activate the endothelium of the
local vasculature, which leads to the expression of several adhesion molecules,
facilitating the extravasation of the leukocytes at the site of infection and
increasing the capillary permeability (87). The increased capillary permeability
allows also the extravasation of complement proteins and coagulation factors,
which support the cellular defense by opsonizing bacteria. Moreover, cytokines
also have vasodilatating effects resulting in an overall local increase in blood
flow, but also to decrease in flow speed in each vessel, which again facilitates
attachment and extravasation of leukocytes. Another result of the endothelium
activation is the activation of the coagulation cascade, which leads to clotting of
some of the outflowing vessels and therefore helps containing the infection
locally (88). Clinically, these local changes can be appreCiated by swelling
(tumor), redness (rubor), heat (calor) and pain (dolor).
Besides these very important local effects, cytokines induce systemic
effects known as the acute phase response (83,84,89,90). The acute phase
response consists of fever, increased permeability of the vasculature, changes in
metabolism and the increased or decreased production of certain proteins by the
liver. The main effectors of the acute phase response are TNF-a, IL-1(3, and IL-6.
In summary, the secretion of these pro-inflammatory cytokines, TNF-a, IL1(3 and IL-6 is the first and very important step of the monocytes response. These
cytokines then trigger a cascade of events, which optimize the local host defense
but also prepare the rest of the body to support the host defense process.
Consequently, an increased or reduced secretion of these cytokines can have
13

Figure 1: Overview of the Inflammatory Response
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detrimental effects to the host. Over-expression of TNF-o results in a lethal
shock, whereas an inadequately weak immune response is also detrimental (9196).
Monocytes and macrophages produce also IL-10. IL-10 is a cytokine with
anti-inflammatory properties, which has in general opposing effects to the proinflammatory cytokines (97-100). It suppresses the further secretion of the proinflammatory cytokines by inhibiting their production in monocytes and
macrophages. This property of IL-10 led to the original name of IL-10: human
cytokine synthesis inhibitory factor. The strong anti-inflammatory properties of IL10 have been demonstrated in models of lethal endotoximic shock, which result
in an exaggerated secretion of pro-inflammatory cytokines, mainly TNF-o. In
these models, injection of IL-1 0 reversed the shock symptoms and increased the
survival of the animals. An appropriate anti-inflammatory response is an
important step to limit systemic and local inflammation and prevent excessive
damage to the host organism.
These data reveal a tightly regulated and ordinarily balanced system of
pro- and anti-inflammatory mediators. The balanced secretion of first proinflammatory followed by anti-inflammatory mediators is believed to be the key
for an adequate host defense. Inadequate secretion of pro-inflammatory
cytokines can result in lethal shock (75,91). Blockade of these cytokines can
increase survival (93,97,98,101). However, an inappropriate suppression of the
immune system makes the host susceptible to over-whelming systemic infections
(94-96,102,103). Unfortunately, neither reduction of the pro-inflammatory
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response nor stimulation of the immune system were successful in clinical trials
(56,57,61,104-107). In retrospect, many of these substances were crude
sledgehammers and the test situations clinically unlikely to respond significantly
to a single addition to an array of therapies already in place. Changes in this
tightly controlled system have profound consequences on the immune response
and therefore survival of the host. In our research, we focus on the role of the
monocyte/macrophage in the initiation of the immune response. We believe that
hypothermia results in dysfunction of the monocyte cytokine secretion and
thereby impairs the host defense.

ROLE AND REGULATION OF THE MONOCYTE
The principle role of monocytes is the recognition of pathogens, initiation
of the immune response and presentation of antigens from phagocytized
pathogens to cells of the adaptive immune system (51,72,79). The secretion of
pro-inflammatory cytokines is the cornerstone of the initiation of the immune
response. Besides these pro-inflammatory cytokines, monocytes produce also
IL-10, which is an inhibitory cytokine and limits the immune response in order to
prevent excessive damage to the host. The secretion of pro- and antiinflammatory cytokines is tightly controlled on several levels with negative
feedback loops within the cell as well as from outside the monocyte.
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Pathogen Recognition and Intracellular Signaling
The first step in the immune response is the recognition of the pathogen
(72,79,80). For this purpose, monocytes are equipped with a variety of extra- and
intracellular PRR's of which Toll-Like Receptor 4 (TLR-4) is one of the best
described. TLR-4 can recognize LPS but also several endogenous proteins such
as heat shock proteins and HMGB1 (79,108-110). Besides TLR-4, at least twelve
other Toll-like receptors have been described. Some of these Toll-like receptors
are localized within the cell in phagosomes and allow recognition of phagocytized
pathogens. Other extracellular receptors are the Receptor for Advanced
Glycation Endproducts (RAGE), which recognizes endogenous proteins and
glycated proteins, which occur in poorly controlled diabetic patients. The
Scavenger receptor is another extracellular receptor, which recognizes mainly
bacterial products but also oxidized lipoproteins. This receptor is believed to
contribute to the formation of arterial plaques (111). Another large group of
PRR's are the Nucleotide Oligomerization Domain receptors (NOD-like
receptors) (112-114). These receptors are mainly located intracellularly.
Intracellular receptors often respond to bacterial or viral RNA and DNA fragments
which are released from digested bacteria or viruses, which infect the cell. The
detection of bacterial RNA is believed to be an important assessment point for
the immune system in order to determine the virulence of the infection (115).
Detection of bacterial RNA indicates the presence of viable, growing bacteria and
results in a more vicious and prolonged inflammatory response compared with
stimulation with LPS alone.
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LPS is bound by the LPS-binding protein, which in turn binds the CD14
surface receptor on monocytes (116). The complex of CD14, LPS and LPSbinding protein associates with TLR-4, resulting in the activation of the TLR-4
signaling cascade. TLR-4 may interact with several down-stream signaling
proteins. However, the seemingly most important signaling protein is Myeloid
differentiation primary response gene 88 (MyD88), which in turn interacts with the
Interleukin-1 Receptor Associated Kinase 1 and 2 (IRAK 1 and 2) (108,117).
IRAK 1 and 2 activate then the TNF-Receptor Associated Factor 6 (TRAF 6),
which is able to activate two central, stress response pathways, the Nuclear
Factor K Beta (NF-KB) and the Mitogen Activated Protein Kinase Pathway
(MAPK). After activation of the TLR-4 signaling pathway, inhibitory proteins are
expressed and inactivate the TLR-4 pathway by targeting the central complex
consisting of IRAK 1/2, and TRAF-6. These inhibitory proteins are phosphatases,
which cleave off the activating phosphate on these proteins. Two of these
upstream inhibitors are the Suppressor of Cytokine Signaling 1 (SOCS-1) and
the SH2 domain-containing inositol 5'-phosphatase 1 (SHIP-1) (118-120).

NF-KB and MAPK.Pathway in the Monocyte Response
Intracellular signaling pathways are crucial to the capability of cells to cope
with changes in their environment, process and integrate incoming signals from
several receptors and to respond in an appropriate manner (121-124). Two
pathways are essential for the monocyte response: the NF-KB and MAPK-
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pathway. Both are activated by a variety of surface and intracellular receptors.
Importantly, there is a broad cross-activation between the NF-KB and the MAPKpathway. An outline of these two pathways is shown in Figure 2.
The activation of TRAF 6 by IRAK 1 or 2 results in the activation of the
Inhibitory K-Kinase (IKK), of which three subtypes, exist. IKK then
phosphorylates the Inhibitory K protein Beta (lkB), which is bound to the NF-KB
complex consisting of the p65 and p50 subunit. The complex of p65/p50 and IkB
is localized in the cytoplasm of the monocyte. Phosphorylation of IkB results in its
degradation and the release of the p65/p50 complex (109, 123-125). The NF-KB
complex is now able to migrate into the nucleus and binds promoter sites of
cytokine genes and other stress response genes resulting in their transcription.
The inactivation of NF-KB occurs by constitutional re-expression of IkB, which
binds the p65/p50 subunit resulting in its inactivation. The importance of this
activation mechanism is that NF-KB itself is a transcription factor and does not
depend on the activation of other transcription factors or their production.
The MAPK-pathway is also activated by TRAF 6. In contrast to the NF-KB
pathway, the MAPK-pathway is organized in three arms and several levels of
protein kinases. The three arms are p38, the extracellular signal-regulated
kinases (Erk 1 and 2), and the c-Jun N-terminal kinases (JNK 1-3). These three
arms can induce expression of a variety of similar or closely related genes such
as pro-inflammatory cytokines (109,121,122,126). However, the Erk-pathway
seems to hold a pivotal role in the induction of the IL-10 production, whereas the
p38 and JNK-arm appear not to be mandatory for IL-10 production (99). Over20

simplified, the p38 and JNK-arms have mainly pro- inflammatory properties,
whereas the Erk-arm also has anti-inflammatory properties, mainly by induction
of IL-10 expression.
The MAPK-pathway is organized in several layers, in which the top layer
activates the subsequent level, which in turn activates the next level. There are a
total of at least three levels, MAPK1 - 3 in which MAPK3 is the first level of
activation and MAPK1 is the level of p38, Erk 1/2, and JNK1-3. TRAF 6 activates
the MAPK31evei by phosphorylation. The MAPK1 proteins, i.e. p38, Erk and
JNK, phosphorylate transcription factors such as the Activated Transcription
Factor 1 (ATF1), c-Jun or c-Fos. The purpose of organization in to these several
levels is that an incoming signal can be amplified resulting in a strong, reliable
activation of the down-stream targets. In contrast to the NF-KB-pathway, the
inactivation of the MAPK-pathway is an active process, which is tightly regulated
and may result in selective inhibition of a certain arm of the MAPK-pathway. The
inactivation occurs mainly on the MAPK1 level by specific so-called Dual
Specificity Phosphatases (DUSP's) or MAPK-phosphatases (MKP's) (127-130).
Most of these DUSP's are specific for one or two of the three arms of the MAPKpathway. DUSP 1 for example inactivates the p38 and JNK arm but not the Erk
arm. This organization offers the opportunity to fine tune the activation of each of
the three arms. There are at least 30 proteins described, which contain the
typical phosphatase domain. However, only eleven of these also contain the
MAPK-binding site. The physiologic role of these DUSP's without MAPK-binding
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Figure 2: Overview of the Inflammatory Signaling Pathways
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Legend Figure 2
The NF-KB and Mitogen-Activated Protein Kinases Pathway (MAPK) are intracellular signaling pathways which are
activated by stress Signals and induce a stress response. TLR-4 recognizes LPS and activates a cascade of signaling
proteins, which results in activation of NF-KB and MAPK. The key activator of NF-KB is the Inhibitory K Kinase (IKK),
which phosphorylates the Inhibitory K Protein

f3 resulting in its degradation.

The NF-KB complex consisting of the p65 and

p50 subunit translocates into the nucleus and activates gene transcription.
The MAPK-pathway is activated by a variety of proteins. This pathway consists of three arms, JNK, Erk and p38. There
are several layers of kinases, which are activated subsequently starting at the MAPK3K level. This arrangement leads to
I'V
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an amplification of the incoming signal. JNK, Erk and p38 activate several transcription factors, which then induce
transcription of the target genes.
There is a very high degree of redundancy in activation of these pathways.

domain is unclear. It appears also that there is a certain tissue specificity of the
DUSP's and only a few of them are expressed in all tissues and cell types.
These DUSP's are newly produced after activation of the MAPK-pathway
within 30min to 1 hour. The degree of up-regulation and also the subtype of the
DUSP, which is up-regulated, can therefore lead to a modification of the MAPKpathway activation and shift the response of the cell. The result of activation of
both, the NF-KB and MAPK pathway, is the production and secretion of cytokines
as well as other proteins, for example heat shock proteins, which increase the
resilience of the cell.

MICRORNAS REGULATE THE MONOCYTE RESPONSE
In the last few years, microRNAs have been recognized to be potent
regulators of cell function (131-134). MicroRNAs are short, single-stranded RNA
fragments with a length of -22 nucleotides (nt). The main role of microRNAs is
the interference of protein production, mainly through a reduction in protein
expression, although an increased protein production has been observed in
starved cells (135).
The biogenesis of microRNAs is outlined in Figure 3. MicroRNAs are
transcribed from DNA like normal genes. These pri-microRNAs are then
processed by Drosha, an enzyme which cleaves RNA-stands, to pre-microRNAs.
The pre-microRNA is transported into the cytoplasm by a specific transporter,
Exportin-5. In the cytoplasm, the microRNA is processed by Dicer, a protein
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similar to Drosha but located in the cytoplasm, into the active, mature microRNA
and is integrated into a protein complex, the RNA-induced silencing complex
(RiSe). Depending on the complementarity of the micro RNA-seed sequence with
the mRNA sequence, the mRNA is either degraded or the binding of the
translation machinery inhibited. A 100% complementarity of the microRNA seedsequence with the mRNA results in degradation of the microRNA, whereas an
80% match results in inhibition of the protein translation. Both processes result in
reduced protein production. Importantly, a change in mRNA-levels is only evident
when the mRNA is degraded. The catalytic active protein, which is able to
degrade mRNA, is the Argonaut 2 protein (Ag02). As of yet, the main function of
microRNAs in a broad sense appears to be the inhibition of protein production
rather than degradation of the mRNA-strand.

MicroRNAs Described in Monocytes
Several microRNAs have been investigated and found to be important in
the monocyte response (136-146). Figure 4 shows some of these microRNAs
and their proposed targets. Among these microRNAs, miRNA-155, -146a, -101,
and -21 are among the best described. We will focus on microRNA-155 in our
research. Depending on the target protein, the microRNAs can either have

a pro-

inflammatory or anti-inflammatory action (139,140,145,147,148). MiRNA-155 and
-101 both target inhibitors of the TLR-4 signaling pathway. Since microRNAs
inhibit protein production, the inhibition of an inhibitor results in a prolonged

25

Figure 3: Biogenesis of microRNAs
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MicroRNAs are transcribed from DNA into pri-microRNA and are then processed
by Drosha into the pre-microRNA. The pre-micro RNA is transported into the
cytoplasm by Exportin-5 and processed by Dicer and integrated into the RNAinduced silencing complex (RISe) . The complementarity of the microRNA-seed
sequence determines the effect on the target mRNA : a 100% match results in the
degradation of the mRNA whereas an 80% match inhibits protein production.
Drosha and Dicer are RNA-processing enzyme located in the nucleus or
cytoplasm, respectively.
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Figure 4: MicroRNAs involved in the Toll-like Receptor Signaling Pathway
Extracellular Space
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Several microRNAs target the TLR-4 pathway. Depending on the target, the
microRNAs can either have pro- or anti-inflammatory properties. The fact that
multiple microRNAs target several proteins on all levels of the TLR-4 pathway
demonstrates a high redundancy and tight control of the activation of the
pathway. Adapted and modified from (137, 139, 144, 146, 149).

27

Figure 5: Action of miRNA-155 and -101 in the TLR-4 Pathway
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MiRNA-155 decreases production of SHIP-1/S0CS-1 and increases activation of
both NF-KB and MAPK-pathway. MiRNA-101 reduces production of DUSP-1
increasing activation of p38 and JNK. The synergistic action of these two
microRNAs increases the production of pro-inflammatory cytokines.
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activation of the TLR-4 signaling pathway. MiRNA-155 targets SOCS-1 and
SHIP-1 both are upstream inhibitors of the TLR-4 signaling pathway and inhibit
IRAK-1/2 and TRAF-6 (139 ,145,149). Up-regulation of miRNA-155 inhibits the
expression of these inhibitors and results in a prolonged activation of the TLR-4
signaling prolonging the secretion of pro-inflammatory cytokines such as TNF-a,
IL-1 ~ and IL-6 (Figure 5) . Because SHIP-1 ISOCS-1 are upstream inhibitors, only
a slight reduction of their expression level can have profound impact on the
activation of the NF-KB and MAPK-pathway. Besides the pro-inflammatory
actions, miRNA-155 can also have anti-inflammatory actions. Suppression of
MyD88 or TAB2 production by miRNA-155 results in a reduced signaling through
the TLR-4 pathway and reduced secretion of TNF-a (140,148). The pro- or antiinflammatory effect of miRNA-155 is time-dependent and depends on the
targeted protein and cell type . MiRNA-101 has pro-inflammatory properties
(Figure 5). MiRNA-101 inhibits DUSP-1 production prolonging the activation of the
p38 and JNK-arm of the MAPK pathway, which also results in an increased
secretion of TNF-a (146). Because miRNA-155 and -101 both target inhibitors of
the same pathway, they have synerg istic function.
In contrast to miRNA-155 and -101 , miRNA-146a targets IRAK-1 and
TRAF-6 to reduce the expression of these two proteins, resulting in a decrease in
the TLR-4 signaling (Figure 4). Therefore, miRNA-146a has anti-inflammatory
properties (136,137,141 ,150,151).
MiRNA-21 is a very well described microRNA in cancer development
because many of its targets are proteins of important signaling pathways (15229

159). One of these target proteins is the Programmed Cell Death Protein 4
(PDCD-4). The exact function of PDCD-4 is unclear, but it has been proposed
that it is involved in the induction of apoptosis . Therefore, up-regulation of
miRNA-21 results in a decrease of PDCD-4 and consequently reduces apoptosis
promoting cancer development. In the monocyte response, Sheedy et al. have
proposed another regulatory loop (143). In this complex feedback loop , PDCD-4
inhibits the transcription of IL-10 mRNA. Up-regulation of miRNA-21 by activation
of the TLR-4 signaling pathway results in a reduction of PDCD-4 expression and
subsequently an increase of IL-10 mRNA, which then will be translated into IL-10
protein . The IL-10 protein will be secreted and acts as the above described
inhibitor of the monocyte response .

Considerations of Target Protein and Timing for Action of MicroRNAs
In order to determine the effects of microRNAs on the immune response, it
is important to consider the expression level of the targeted protein. MicroRNAs
can only inhibit the production of proteins. Therefore, already existing proteins
are not affected immediately by newly expressed microRNAs . Th is is the case for
miRNA-146a , which targets IRAK-1 and TRAF-6 , but also for miRNA-155 when
the target is MyD88 or TAB2. All these proteins are existing proteins and part of
the TLR-4 signaling pathway. These proteins are essential for proper function of
the TLR-4 pathway and must respond immediately if a pathogen is detected . Upregulation of miRNA-146a or miRNA-155 will not affect these existing proteins.

30

Only the re-expression of these proteins will be affected and a reduction in downstream signaling will only result in a delayed manner. Consequently, the
inhibitory effect of miRNA-146a and miRNA-155 up-regulation will be delayed .
In contrast, the effect of miRNA-155 is immediate when SHIP-1/S0CS-1
are targeted ; both proteins are expressed after activation of the TLR-4 pathway
and act as a negative feedback loop . Up-regulation of miRNA-155 will inhibit the
production of these two inhibitors of the TLR-4 pathway immediately.
Consequently, up-regulation of miRNA-155 results in increased down-stream
signaling . Up-regulation of miRNA-101 has the same effect. DUSP-1 is also
newly expressed after stimulation of the TLR-4 pathway. The up-regulation of
miRNA-101inhibits the production of DUSP-1 immediately and will also increase
the activation of the p38 and JNK-arm of the MAPK-pathway. However, the Erkarm will not be affected .

EFFECT OF TEMPERATURE ON MONOCYTE RESPONSE
The effect of temperature on the monocyte response has been
investigated in order to identify potential mechanisms, which may explain , why
hypothermic patients experience such detrimental outcomes. Some of our own
and other published data are conflicting . One of the most consistent results is the
effect of hypothermia on cytokine expression in human monocytes or peripheral
blood mononuclear cells (PBMCs) cultu res . Hypothermia reduces the initial
secretion of early, pro-inflammatory cytokines compared to 3rC , but results in
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an increased and prolonged secretion of TNF-o, IL-1 ~ and IL-6 24h or longer
after initial stimulation (18,20,23,62, 160-163). In contrast to the pro-inflammatory
cytokines, the expression of IL-10 was found to be reduced under hypothermic
conditions in the same studies and some others (21,164). HLA-OR was also
found to be reduced in hypothermia. Furthermore, rewarming seems to reduce
the detrimental effects of hypothermia on HLA-OR expression (165).
The only study to our knowledge , which investigates cytokine levels in
hypothermic patients without cardiovascular operation, was conducted in
patients, who were deliberately cooled after successful out-of-hospital
reanimation after cardiac arrest. In this study, IL-6 was found to be higher in the
hypothermic group, whereas TNF-o was not different (166). Supporting the
hypothesis that hypothermia impairs the immune response , the rate of bacterial
colonization was higher in hypothermic patients although no difference in
infectious complications was found . Another study in which therapeutic
hypothermia after cardiac arrest was applied , found a significantly increased rate
of early onset pneumonia in hypothermic patients (167). Both studies report a
higher survival rate in patients with therapeutic hypothermia, which is likely due
to the beneficial effect of hypothermia on the recovery of the hypoxic brain injury.
In a study with brain injury patients, IL-6 was found to be elevated for a longer
period in the jugular vein of normothermic patients and a much more rapid
decrease in jugular IL-6 levels in hypothermic patients (168). Since the difference
in IL-6 was only found in the jugular vein , IL-6 may rather mirror the cytokine
levels in the brain than the systemic response to hypothermia.
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Animal models are of limi.ted value in investigating the effects of
hypothermia. In rodents , which are almost exclusively used for these
experiments, the development of hypothermia is a physiologic process in sepsis
and therefore probably not detrimental as it is for humans (169). Consequently,
the data are conflicting . Some authors found a detrimental effect of hypothermia,
whereas others proposed a beneficial effect. Torossian et al. found detrimental
effects of hypothermia on survival in a bacterial peritonitis model in rats
(170 ,171). Huet et al. and Taniguchi et al. found a beneficial effect of
hypothermia (172 ,173). Importantly, these two studies used LPS as challenge
and not live bacteria as Torossian et al. in their studies, which may contribute to
the opposing results . All studies found an increase of IL-1 0 in hypothermic
rodents, which is in strong contrast to the available in vitro data from human
cells. In line with the human data , restoration of normothermia was found to
increase survival in a bacterial peritonitis model (174). The suitability of mice for
investigation of temperature regulation and effects of temperature has recently
been questioned both scientifically and teleologically (175).
Besides the investigation of cytokines, some studies have examined the
effect of hypothermia on gene expression and pathway activation . Fairchild et al.
found in a series of studies that hypothermia affects the NF-KB pathway (19 ,23).
These investigators found increased activation of IKK, delayed re-expression of
IkB and prolonged nuclear localization of the NF-KB complex. These findings
would explain the prolonged secretion of pro-inflammatory cytokines (19,23). Arai
et al. confirmed the prolonged NF-KB activation in hypothermia (164). In line with
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a profound impact of hypothermia on cell homeostasis, Sonna et al. found also a
strong impact of hypothermia on the whole genome expression in the human
monocytic cell line THP-1 and liver cells (24,176). Interestingly, genes involved in
the immune response and signaling pathways were particularly strongly affected
by hypothermia. To date, there is no data on effects of hypothermia on the
MAPK-pathway in monocytes or macrophages. The existing data in Human
Umbilical Vein Endothelial Cells (HUVEC) and astrocytes indicates that these
pathways are also affected by hypothermia (25,177,178). Of particular interest is
the finding of Yang et aI, that the reduced JNK-activation in hypothermia in their
model of ischemia/reperfusion injury is due to an increased expression of DUSP1 and not due to an increased up-stream signaling (177).
In summary, hypothermia was found to increase and prolong the secretion
of pro-inflammatory cytokines and to reduce the expression of IL-10 in human
cell cultures. As a possible underlying mechanism , hypothermia prolongs NF-KB
activation in monocytes.
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CHAPTER III
HYPOTHESIS, SPECIFIC AIMS AND EXPERIMENTAL PLAN

A) Key Objective
To investigate the effects of clinically-relevant altered temperatures
on primary monocyte function such as cytokine production and to identify
mechanisms likely to be responsible for increased rate of infectious
complications and death in hypothermic surgical patients.

B) Hypothesis
Hypothermia dysregulates elementary cell functions such as the
activation of inflammatory signaling pathways and gene expression. We
hypothesize that hypothermia increases the activation of the NF KB and
MAPK-pathway. This increased pathway activation leads to increased
expression of pro-inflammatory genes and miRNA-155 resulting in a
prolonged secretion of pro-inflammatory cytokines in hypothermia.
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C) Specific Aims
a. Specific Aim 1: Investigation of NF-KB and MAPK pathway
activation under hypothermic and hyperthermic conditions in
isolated monocytes.
b. Specific Aim 2: Analysis of expression of miRNAs miR-155 at
32°C to 39°C.
c. Specific A im 3: Verification of the effect of the dysregulated
miRNA-155 on the cellular response through the use of miRNA
mimics and antagomirs on the cytokine production .
d. Specific Aim 4: Investigation of the suppressive role of IL-10 on
miRNA-155 expression and the prolonged TNF-a production at
32°C and 39°C .

D) Experimental Plan
The purpose of this project is to investigate how hypothermia
modulates the monocyte response on the cellular level and which
processes lead to the observed differences in cytokine secretion . We
analyze each step of the monocyte response , starting with the activation
of the signaling pathways NF-KB and MAPK. If we observe differences in
the activation of these pathways, a subsequent difference in gene
expression can be expected . Gene expression in our understanding
includes mRNA and microRNAs, mainly miRNA-155 for our purposes.
Identification of differential expression of miRNA-155 in hypothermia
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should result in differences in secretion of pro-inflammatory cytokines . To
confirm the role of miRNA-155, we will up-regulate or suppress the
expression of miRNA-155 and demonstrate its effect on TNF-a . The last
purpose of our research is to determine, which role negative feedback
loops play in the regulation of the monocyte response . Modulation of the
action of IL-1 0 allows determining its effect on cytokine gene expression
and cytokine secretion as well as miRNA-155 expression . An outline of the
research plan is showed in Figure 6.
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Figure 6: Research Plan and Investigated Steps of the Monocyte Response
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We investigate the monocyte response stepwise and determine the effect of hypothermia on each of these steps.

The first step is the activation of the NF-KB and MAPK-pathway followed by the expression of cytokine mRNA and
miRNA-155. The role of miRNA-155 on TNF-a secretion and the impact of the negative feedback loop of IL-10 on
miRNA-155 is also analyzed.

E) Methods
E1) Study Subjects
Approval of the study protocol was obtained from the University of
Louisville Institutional Review Board prior to enlisting any study subjects
(HSPPO 08.0018). Written informed consent was obtained from all
participants. Volunteers with any signs of acute sickness, history of
chronic conditions such as diabetes mellitus or immune-suppressive
disorder and subjects with chronic medication use were excluded. We
enrolled a total of 16 healthy donors, although the majority of experiments
were conducted with seven donors per experiments. The age of the
participants ranged from 19 - 49 years.

E2) Monocyte Isolation
Venous blood was collected in EDTA Vacutainers (Becton
Dickinson, Franklin Lakes, NJ). Primary human monocytes were isolated
using the magnetic cell sorting technique according to manufacturer's
instruction. The collected whole blood was incubated with Human CD14
MicroBeads (Miltenyi Biotec, Auburn, CA) for 15min in an incubator at

3rC. After washing, the blood was resuspended in the original volume
with MACS Separation Buffer (Miltenyi Biotec, Auburn, CA) and run
through Whole Blood Columns (Miltenyi Biotec, Auburn, CA). After
isolation, the columns were washed three times and the monocytes eluted
from the columns with MACS Elution Buffer (Miltenyi Biotec, Auburn, CA).
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The cells were washed twice with Phosphate Buffered Saline (PBS) and
counted. The purity of the isolated monocytes was >95% as determined
by Flow Cytometry.
The primary monocytes were cultured in 1640 RPMI medium (MP
Biomedicals, Solon, OH) supplemented with 10% heat-inactivated defined
Fetal Bovine Serum, 2nM L-Glutamine and 100lU/mi penicillin, 100IJg/mi
streptomycin and 250ng/ml amphotericin B (all items purchased from
Thermo Scientific, Waltham, MA). Cells were cultured in a concentration of
0.25 x 106 cells/ml in a humified incubator with 5% CO 2 .The temperature
varied according to the experimental conditions. In general, the monocytes
were cultured at 32°C or 39°C for the different experiments. 39°C was
chosen to avoid the strong induction of a heat shock response (179-181).
Preliminary experiments with 34°C and 3rC demonstrated higher TNF-a
levels and lower IL-10 levels in 34°C compared to 3rC. However, the
high inter-subject variation of the cytokine response ameliorated some of
the temperature differences. We therefore decided to use 32°C and 39°C
in order to enhance the temperature induced differences. If the cells were
rested or stored, the culture temperature was 3rC. The monocytes were
cultured in 50ml polypropylene tubes as cell suspension.
Lipopolysaccharide (LPS), 1OOngper 0.25 x 106 cells (E. coli 0111 :84;
Sigma-Aldrich Co., St. Louis, MO) was used for stimulation. After
incubation for the indicated time-periods, the monocytes were centrifuged,
the supernatant was collected and stored at -80°C until measurement. The
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cell pellet was washed with PBS and transferred to 1.5ml centrifugation
tubes and centrifuged for 3min at 10,000rpm (Eppendorf MiniSpin).

E3) Phosflow Pathway Analysis
For the pathway analysis, the freshly isolated monocytes were
rested at 3rC for 24h until further use. After 24h, cells were washed and
resuspended in fresh medium (10% FBS supplemented 1640 RPMI). Cells
were stimulated with LPS (100ng per 0.25 x 106 cells) and then incubated
for the indicated time pOints at either 32°C or 39°C. There was no preincubation at the corresponding temperature. For definition of baseline
pathway activation, unstimulated monocytes cultured at 3rC for the
duration of the experiment were used (=Oh time point).
In preliminary experiments, we also investigated the activation of
NFKB at 3rC. Table 1 shows the Mean Channel Fluorescence (MCF) at
15min and 20min after LPS at 32°C, 3rC and 39°C. NFKB activation at

3rC lies between 32°C and 39°C.
After the indicated time, the monocytes were immediately fixed for
10min at 3rC with a pre-warmed Formaldehyde solution (final
concentration 3.2%) in order to preserve the phosphorylation status of the
pathways. Cells were then washed twice with wash Buffer containing FBS
(FBS wash Buffer, BO Bioscience, San Jose, CA). The monocytes were
permeabilized with pre-chilled 100% methanol at -20°C for 30min in order
to allow the antibodies access to the pathway epitopes. After three
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washes, cells were resuspended in 100fJI FBS-wash buffer and separated
into two tubes. One tube was used for analysis of NF-KB and p38
activation; the second tube was used for analysis of Erk and JNK
activation. Samples were stained for 1h in the dark at room temperature.
The following antibodies were used (all BO Bioscience Phosflow
antibodies, San Jose, CA): phospho-p38 MAPK (pT180/pY182), Alexa
Fluor® 488; phospho-ERK1/2 (pT202/pY204), Alexa Fluor® 488;
phospho-JNK (pT183/pY185), Alexa Fluor® 647; NF-KB p65 (pS529),
Alexa Fluor® 647.
After staining, cells were washed twice and resuspended in 250fJI
FBS-wash buffer and immediately analyzed. A FACS Calibur (BO
Bioscience, San Jose, CA) was used to acquire the samples. We counted
10,000 events for each sample. The freely available online-software
cytobank.org, which was specifically developed for analysis of Phosflow
samples, was used for analysis. Example histograms for NF-KB activation
are shown in Figure 7.

E4) RNA Isolation
Total RNA was isolated from the monocyte pellet using the RNeasy
Mini Kit (Qiagen, Valencia, CA). Concentrations and purity of the RNA
were determined with the Nanodrop N-1 000 (Agilent Biosystems, Santa
Clara, CA). All samples fulfilled the quality criteria (A260/A260 ratio
between 1.9 and 2.1).
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Table 1: NFKB Peak Activation at 32°C, 3rC and 39°C

15min post LPS

20min post LPS

(MCF)

(MCF)

Temperature

32°C

1148.31

1061.81

37°C

1099.83

975.83

39°C

975.23

772.36

Comparison of peak activation between 32°C, 3rC and 39°C of the NFKB
pathway in one preliminary experiment. The highest activation is recorded
at 32°C and remains elevated. The lowest activation is measured at 39°C
while 3rC is in between.
MCF: mean channel fluorescence
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Figure 7: Example of NF-KB Activation at 32° and 39°C

Oh
lSmln
30mln
4Smln

lh

Oh

1---- --

lSmln

I-------~-I

I - - - - --

J - - - - --

x---f

I - - - --'-'O'::=__:,

4Smln 1--_ __

I - - - --.........:::-it

1 - - - - --

<--f

30min

lh

oL:....-£

2h

2h

---01..-...,.

1------ -
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channel intensity in a logarithmic scale). In addition, the degree of
activation is color-coded with brighter colors indicating

a higher degree of

activation. The different levels of histograms in the y-axis indicate the
different time points. The 2h time point at 39°C reaches almost baseline
levels, whereas 32°C remains clearly activated. In addition, the peak level

of activation at 32°C is higher than at 39°C.
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ES) Cytokine Measurements

TNF-a, IL-6, and IL-10 levels were determined by enzyme-linked
immunosorbent assays (ELISA) (eBioscience, San Diego, CA) in 96-well
plates according to manufacturer's protocol. All samples were analyzed in
duplicates; cytokine levels of samples were determined by a standard
curve using recombinant human TNF-a, IL-6, or IL-10.

ES) MicroRNA and MessengerRNA Expression

For expression analysis of miRNA-155 TaqMan single microRNA
assays were used according to manufacturer's instruction (Life
Technologies, Foster City, CA). The housekeeping gene U6 was used for
normalization. An exemplary amplification plot is shown in Figure 8.
For expression of TNF-a and IL-10 mRNA, complementary DNA
(cDNA) was generated using the High Capacity cDNA Reverse
Transcription Kit (Life Technology, Foster City, CA). TaqMan single gene
assays for human TNF-a and IL-10 (Life Technologies, Foster City, CA)
were then used for assessment of gene expression. 18s was chosen as
internal control.
The Polymerase Chain Reactions (PCR) were run on a StepOne
Plus ReaITime-PCR-System using Fast Advanced Master Mix and the fast
protocol (all products purchased from Life Technologies, Foster City, CA).
Fold changes were calculated using the MCT -method (182).
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Figure 8: Exemplary Amplification Plot for miRNA-155
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difference in Ct-values between the housekeeping gene U6 and miRNA-155 is used to calculate the fJ.Ct. The
difference between the control sample and the sample of interest allows the determination of the fJ.fJ.Ct, which can
be transformed into Fold Change.

E7) MicroRNA-Transfection

In order to demonstrate the effect of miRNA-155 on the prolonged
expression of pro-inflammatory cytokines, we transfected the monocytes
with miRNA-155 mimics and antagomirs. MicroRNA-mimics are premicroRNAs, which are processed by Dicer and become part of the RISC
and act in the same way as endogenous microRNAs. MicroRNAantagomirs are the anti-sense strand of the mature micro RNA of interest.
The binding of the antagomir with the target microRNA leads to the
degradation of the microRNA by the same process as described for
silencing RNAs (siRNA) (183). Negative controls are RNA-strands, which
have the same hairpin structure like a natural pre-microRNA and are also
processed by Dicer. However, the seed-sequence of the negative controls
is not complementary to any known gene and has therefore no biologic
action.
For this experiment, monocytes were isolated as described and
then immediately transfected with either miRNA-155 mimic, negative
control or miRNA-155 antagomir. We used the N-TER nanoparticle
transfection system for this purpose according to the manufacturer's
instructions (Sigma-Aldrich Co., St. Louis, MO). The miRNA-155 mimic
and negative control were incubated in a concentration of 40nM, whereas
the miRNA-155 was incubated in a concentration of 80nM. MicroRNAmimics, antagomirs and negative control were purchased from Ambion
(Life Technologies, Foster City, CA).
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After 24h of transfection, the cells were washed and resuspended
in fresh RPM I-media with 10% FBS. The cells were then stimulated with
LPS for another 24h at the appropriate temperature, 32°C or 39°C. After
24h of LPS-stimulation, the supernatant was collected for cytokine
measurements and the total RNA was isolated for analysis of micro RNA
expression. Cell viability at all time pOints was >90% as determined by
flow cytometry and Trypan Blue.

ES) IL-10 Addition I Anti-IL-1 O-Receptor Blockade

In order to elucidate the role of the IL-10 feedback loop, we added
recombinant human IL-10 (rhIL-10, Sigma-Aldrich Co, St. Louis, MO) or
blocked the action of IL 10 by blocking the IL-10 receptor. For the IL-10
addition experiment, monocytes were isolated and stimulated with LPS at
32°C or 39°C as outlined above. After 4h of LPS-stimulation, 20ng of rhlL10 for a final concentration of 5ng/ml were added to the cell culture tubes
in both temperatures for the remaining time of 12h and 24h. The 4h time
point at which IL-10 was added was chosen based on preliminary
experiments. At this time point, IL-10 is being secreted by monocytes after
LPS stimulation.
In order to block the action of IL-10 the isolated monocytes were
incubated for 1h at 3rC with 10IJg of anti-human IL-10-receptor antibody
(a-subunit, Sigma-Aldrich, St. Louis, MO). We performed a dilution series
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in order to determine the amount of anti-IL-10-receptor antibody, which
can block the action of IL-1 0 (Figure 9). After incubation with the antibody,
cells were stimulated with LPS and incubated for the indicated time point
at 32°C and 39°C. These experiments were conducted with the same
donor at the same time with both treatments in both temperatures. In
addition, untreated samples cultured at 32°C or 39°C were used as
controls. At the indicated time pOints, supernatant was collected and total
RNA isolated until further analysis.

E9) Statistical Analysis
For all experiments, monocytes from the same person were used
and the different temperatures or treatments were compared against each
other within the same person. Therefore, a related sample test was used.
For two comparisons, the Wilcoxon ranked sign-test was used; for multiple
comparisons, Friedman's Two-Way Analysis of Variance by Ranks was
used. Data are presented as mean ± SEM. SigmaPlot 11.0 was used for
presentation of the data (Systat Software Inc., San Jose, CA). Statistical
analysis was performed with SPSS 18.0 (PASW Statistics 18, IBM,
Chicago, IL). Results were considered significant at p<0.05.
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Figure 9: Effect of Different Amounts of Anti-IL-1 0 Receptor Antibody on TNF-a
and miRNA-155
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CHAPTER IV
EFFECT OF TEMPERATURE ON CYTOKINE EXPRESSION
The secretion of cytokines by cells of the immune system serves several
important purposes. Gytokines serve as messengers among different immune
cells and coordinate the immune response in order to contain infections (47,51).
The first step in a successful engagement of the immune system is the signal
that an invading pathogen has been discovered. This signal attracts other
leukocytes in relatively large numbers with the goal to clear the infection. Tissue
macrophages and dendritic cells serve exactly this cause. These cells patrol
through the tissues and phagocytize foreign and endogenous material.
Pathogens such as bacteria are recognized by a variety of receptors like the
TLR-4 receptor (72,79,80). These receptors signal through signaling pathways
and induce secretion of cytokines. The first response is the secretion of
preformed cytokines, which are stored in vesicles. Secretion of these preformed
cytokines allows an immediate response to any signs of danger. These proinflammatory cytokines activate the local endothelial cells and attract other
immune cells such as neutrophils and monocytes from the blood. These cells
evade at the site of the infection the blood stream and engage in the immune
defense replenishing and supporting the local cells.
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The second purpose of cytokines, after activation of the initial immune response,
is to limit the host response to the infected tissue and avoid damage to the host.
An uncontrolled release of pro-inflammatory cytokines may lead to severe,
detrimental effects such as generalized vasodilation resulting in shock or
systemic activation of the coagulation system known as disseminated
intravascular coagulation (DIG) (75,91). To prevent the systemic spread of the
immune response, anti-inflammatory feedback loops are automatically activated
after the first detection of LPS by a local tissue macrophage (56,97-100).
IL-10 was the first described anti-inflammatory cytokine. Its original name
human cytokine synthesis inhibitory factor (GSIF) describes clearly what the
function of IL-1 0 is. IL-10 suppresses the production of pro-inflammatory
cytokines directly in any immune cell. It also stimulates its own production and
the production of other, anti-inflammatory cytokines such as Transforming
Growth Factor-f3 (TGF-f3). Furthermore, IL-10 induces the development of a
certain subtype of T-helper cells such as T H2 T-cells and regulatory T-cell (Tregs).
T H2 T-cells stimulate wound healing and the switch of 8-cells to the production
IgG-antibodies (47). This is in contrast to the T H1 T-cell, which produces proinflammatory cytokines and stimulate the activity of macro phages and cytotoxiC
T-cells (G08+). Tregs are another subtype of T-cells, which suppress the immune
system. The exact mechanism how these cells function remains unclear. It has
been suggested that they secret IL-10 and suppress the function of proinflammatory immune cells by transferring anti-inflammatory microRNAs such as
miRNA-146a into T-cells (184,185).
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Taking together, these results suggest that the key to an appropriate
immune response is the balanced production of first pro-inflammatory cytokines
followed by the production of anti-inflammatory cytokines. It has been suggested
that a cause for the post-traumatic multiple organ dysfunction syndrome (MODS)
without sepsis is prolonged and unbalanced secretion of pro-inflammatory
cytokines (186,187). In this concept, the increased and prolonged secretion of
pro-inflammatory cytokines is followed by a profound and prolonged suppression
of the immune system, also described as immune-paralysis or Compensatory
Anti-Inflammatory Response Syndrome (CARS).
Hypothermia dysregulates the secretion of cytokines and this effect may
contribute to the detrimental effect of hypothermia. The available data in human
in vitro cultures indicate that hypothermia results in a delayed, but increased and

prolonged secretion of pro-inflammatory cytokines after LPS stimulation
(18,20,161,163). In contrast, hypothermia decreases the production of antiinflammatory cytokines such as IL-10 (21,22,163).
The purpose of the first experiment was to determine, how hypothermia
affects the production of cytokines in our model and if we can reproduce the
published results.
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RESULTS
Monocyte Purity and Viability
In order to achieve reliable results from our investigations, we first
determined the purity of our monocyte culture. We confirmed a purity >95% after
the isolation process for every donor. An example of a flow scatter plot is shown
in Figure 10. Next, we monitored the viability of the monocytes over time. Figure
10 also demonstrates a scatter plot of a sample of the same donor after 36h of
LPS stimulation at 39°C. There is a slight increase in size and granularity of the
monocytes as indicated by a shift of the population to the right (size) and
upwards (granularity). These changes are explained by the stimulation with LPS
and the subsequent response of monocytes with production of cytokines and
phagosomes. Importantly, there is no significant change of cells outside the gate
(R1), which would indicate disintegration and necrosis or apoptosis of the
monocytes.
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Figure 10: Flow Scatter Plot of Freshly Isolated Monocytes and 36h after LPS
Stimulation
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One distinct cell population can be determined in both graphs. The size (forward
scatter - FSG) and granularity (side scatter - SSG) are typical for monocytes.
Events outside the left side of gate R1 are considered cell debris such as partial
lysed red cells or platelets, which rema in in

a low amount after the isolation

process. The monocyte population remains at the same location after 36h of LPS
stimulation. However, there is

a slight increase in size (shift to the right on the

forward scatter - FSG) and granularity (upwards shift on the side scatter - SSG) .
This is

a typical finding of activated monocytes. There is an insignificant increase

of cells in the left side of gate R1 . These cells are intact and express all receptors
but are becoming necrotic or apoptotic.
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Secretion of Pro-Inflammatory Cytokines

Tumor Necrosis Factor Alpha - TNF-a
Figure 11 shows TNF-a levels over 36h at 32°C and 39°C, respectively.
The TNF-a levels rose quickly after LPS-stimulation. Six hours after LPSstimulation TNF-a levels were significantly higher at 39°C than at 32°C (p <
0.001). The TNF-a levels at 39°C peak at 12h and decay rapidly over the next
24h. In contrast, the rise of TNF-a at 32°C is delayed but peaks at 24h with only
little decrease at 36h. The differences in TNF-a are significant at 24h and 36h
between 32°C and 39°C (p < 0.05).

Interleukin-6 - IL-6
Changes in IL-6 were comparable to TNF-a. Similar to TNF-a, IL-6
increases rapidly at 39°C at 6h and is significantly higher than at 32°C (Figure
11). This initial response was very uniform among the different donors as
indicated by the small error bars. At 12h and 24h, there was no difference
between the two temperatures but the IL-6 levels at 32°C increased until the 36h
time point whereas the IL-6 levels at 39°C peak at 24h and begin to decrease
afterwards. The prolonged and increased secretion of IL-6 at 32°C led to
significantly different IL-6 levels at 36h. Of note, there was considerable variation
of IL-6 levels among the different subjects as indicated by the large error bars.
Because every donor showed a similar influence of temperature on IL-6, the
differences at 36h are statistically significant.
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Secretion of Anti-Inflammatory Cytokine

Interleukin-10 - IL-10
Changes in the levels of IL-10 were reversed in comparison with TNF-a
and IL-6 (Figure 11). IL-10 started to rise with very low levels at 6h at 39°C
whereas essentially no IL-10 was detectable at 32°C. After 6h, the IL-10 levels
rose notably at 39°C until they reached a peak at 24h followed by a slight
decrease. In clear contrast to 39°C, IL-10 rose slowly at 32°C and never reached
comparable levels. The IL-10 differences between the two temperatures are
statistically highly significant at every time point (all p < 0.001).
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Figure 11: TNF-a, IL-6 and IL-10 Over 36h at 32°C and 39°C
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30

Legend Figure 11

Both pro-inflammatory cytokines show

a

comparable influence of

temperature. At 6h, the levels of TNF-a and IL-6 are higher at 39°C. However, at
the prolonged time pOints 24h and 36h, TNF-a and IL-6 are higher at 32°C.
In contrast, IL-10 is higher at 39°C at al/ time pOints. The IL-10 levels at
32°C never reach comparable levels to IL-10 at 39°C.
* indicates p < 0.05; data are presented as mean ± SEM
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DISCUSSION
Cytokines are important players in the immune response because they are
the first response after recognition of a pathogen or tissue injury and this initial
response is also the trigger of a sequence of events, which should result in
clearance of the infection without damaging the host. Therefore, an inappropriate
secretion of cytokines may result in detrimental effects on the host. An
unbalanced, exaggerating immune response can induce tissue damage, shock,
multiple organ dysfunction and ultimately death (75,186). An insufficient immune
response is not able to contain the infection and would result in a first local than
systemic spread of the pathogens resulting in an overwhelming infection.
Hypothermia has been shown to affect the secretion of cytokines
(18,20,161). The available data of human cell cultures indicates that hypothermia
diminishes the early response but results in a prolonged and increased
production of pro-inflammatory cytokines. There is an on-going debate, which
part of the response is clinically more important. Depending on the focus of the
authors, some reports underline the diminished pro-inflammatory response in the
early phase (20,178). Others believe that the prolonged and sustained secretion
of pro-inflammatory cytokines is more important and will have long lasting effect
on the ability of the host to fight infections. The data on anti-inflammatory
cytokines is sparse. In vitro models demonstrate in general a decrease in IL-10
production in hypothermia (20,21).
I believe that the prolonged and increased production of pro-inflammatory
cytokines such as TNF-a and IL-6 is more important for the long-term than the
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initial reduction in pro-inflammatory cytokines in hypothermia. Exaggerated
production of TNF-a can induce multiple organ failure and death (91). The more
important effect of hypothermia in our results seems to be on the counterregulatory part of the immune response, the anti-inflammatory phase.
Administration of IL-10 can reduce almost all of the detrimental effects of TNF-a
(97,98). We found that IL-10 was consistently higher at 39°C than at 32°C and
believe that this result may be of greater importance and the lack of IL-10 at 32°C
may influence the prolonged pro-inflammatory response. The value of an
appropriate anti-inflammatory immune response has been demonstrated in
several models, in which the exaggerated secretion of pro-inflammatory
cytokines is the main pathophysiologic mechanism of shock and administration of
IL-10 can rescue these animals (97,98). Others have found that IL-10 is the
primary inhibitor of leukocyte influx in the peritoneum and that macrophages are
the principle source, also indicating the importance of counter-regulatory
mechanisms (188).
Taking together, these results suggest that hypothermia shifts the overall
response pattern of the monocytes into a pro-inflammatory response with a
prolonged and increased secretion of pro-inflammatory cytokines. At the same
time, the natural negative feedback loop with IL-10 seems to be suppressed in
hypothermia. In contrast, 39°C results in a reduced and shortened immune
response with a strong induction of the anti-inflammatory IL-10.
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CHAPTER V

ANALYSIS OF THE NF-K-B AND MAPK SIGNALING PATHWAYS AT
DIFFERENT TEMPERATURES
Intracellular signaling pathways control the response of the cell by
integrating signals from surface receptors as well as other information on cell
homeostasis (109,121,123). Detection of pathogen associated molecules, the socalled PAMPs, by surface and intracellular PRR's results in a strong activation of
stress response pathways. Two major stress response pathways are the NF-KB
and the MAPK-pathway. Both pathways activate the production of proteins,
which increase the stress resistance of the cell such as heat shock proteins. The
expression of these proteins is essential; otherwise the cell would not survive the
insult (180,181,189). In addition to supporting the survival of the cell, heat shock
proteins also serve as endogenous danger signals for the immune system
(alarmins) amplifing the immune response (77). The second goal of the activation
of the signaling pathways is to orchestrate the response of the whole body in
order to eliminate the invading pathogen. Pro-inflammatory cytokines have local
effects, which result in the extravasation of immune cells but also systemic
effects such as fever and the initiation of the acute phase response. All of these
measures enhance the ability of the host to defend it.
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Modulation of the activation of these pathways has therefore a profound effect on
the response of the cell. Temperature has been shown to affect pathway
activation profoundly (23,160,177). In human monocytic cell lines, NF-KB
activation was found to be increased and prolonged in hypothermia (19,23). In
human endothelial cells, JNK activation was decreased in hypothermia leading to
decreased apoptosis (177). The data on endothelial cells cannot necessarily be
directly adapted to monocytes because the stimuli for the cells are different and
also so is the response pattern to stress. To our knowledge, there is no data
available on pathway activation under hypothermic conditions in primary human
monocytes.
Based on the previous results with highly distinct cytokine secretion
between 32°C and 39°C, we hypothesize that the activation of the NF-KB and
MAPK-pathway is different. A prolonged activation of the pro-inflammatory
pathways, NF-KB, p38 and JNK would explain the prolonged TNF-a secretion at
32°C. The strong production of IL-1 0 at 39°C might also be explained by

.

differences in pathway activation. The mechanism, which lead to the production
of IL-10 are poorly understood and vary greatly among different cell types (99).
However, the available data suggests that the Erk-pathway is pivotal for the
induction of IL-10 in macrophages (99).
The purpose of this experiment was to assess the activation of both, the
NF-KB and MAPK pathway under hypothermic conditions (32°C) in the same cell
at the same time and compare it to 39°C. Measuring the activation of these
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pathways in the same experiment and same primary cells reduces the
confounding factor of repetitive experiments and the associated variation.

RESULTS
Activation of the NF-KB pathway
NF-KB was rapidly activated peaking 15min after LPS stimulation in both
temperatures (Figure 12). After 15min, there was a decrease in NF-KB activation
until 2h at both temperatures. The degree of activation of NF-KB at 32°C was
significantly higher at 15min than at 39°C. This difference in activation remained
over the whole investigated period. NF-KB was increased and its activation was
sustained at 32°C at every measured time point. Of note, NF-KB remained
activated at 32°C at 2h, whereas at 39°C, the degree of activation reached
baseline values.

Activation of p38 of the MAPK-pathway
Similar to NF-KB, p38 was also maximally activated after 15min followed
by a decrease in activation until 2h (Figure 12). P38 reached baseline levels at
2h at 39°C but remained slightly elevated in hypothermia. Hypothermia also
increased and prolonged the activation of p38. There was no effect of
temperature on 15min; but at 30min, 45min, 1hand 2h, p38 was stronger and
longer activated at 32°C than at 39°C. The activation of p38 reached baseline
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levels at 39°C after 45min, whereas p38 remained active at the 2h time point at
32°C.

Activation of JNK of the MAPK-pathway
Figure 12 outlines the activation of JNK over time. at 39°C, JNK activation
peaked at 15min followed by decay in activation and the baseline was reached
after 45min, very comparable to p38. This is in contrast to JNK-activation at
32°C. The peak activation was recorded at 30min instead of 15min resulting
again in an increased and prolonged activation in hypothermia. Similarly to p38,
there was no effect of temperature on the activation at 15min and at 2h. JNK
remained slightly activated at 2h in hypothermia.

Activation of Erk of the MAPK-pathway
While the activation of NF-KB, p38 and JNK of the MAPK-pathway was
comparable with increased and prolonged activation under hypothermic
conditions, Erk-activation is different (Figure 13). The peak activation at 39°C
was at 15min followed by a gradual decrease. The baseline was reached after
1h. The peak activation of Erk at 32°C never reached the same level as at 39°C.
There was a clear activation at 15min, but it plateaued after 30m in and remained
elevated in comparison with 39°C at 30min, 45min and 1h. The baseline was
reached after 2h in both temperatures.
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Figure 12: Activation of the NF-KB, p38 and JNK
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Legend Figure 12
Hypothermia has the strongest effect on NF-KB activation. The increase in
activation at 32°C is five-fold and remains 2.2-fold increased 2h after initial
stimulation.
The peak activation is not influenced by temperature. Hypothermia prolongs the
activation of p38.
JNK is the only pathway reaching peak activation at 30min at 32°C but is also
prolonged and increased activated.
MCF: Mean Channel Fluorescence
* indicates p < 0.05; data are presented as mean ± SEM
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Figure 13: Activation of Erk of the MAPK-pathway
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± SEM

DISCUSSION
The activation of inflammatory signaling pathways is an important step in
monocyte response and in the initiation and orchestration of the immune
response. Our data demonstrate that hypothermia increases and prolongs the
activation of pro-inflammatory signaling pathways, namely NF-KB, p38 and JNK,
over the whole 2h investigation period. This is in line with results from Fairchild et
al. (19,23). In contrast, the degree of activation of Erk is higher at 39°C at 15min
and this level of activation is not reached at 32°C. However, Erk activation
remains prolonged and increased after 30min - 1h in hypothermia as it is the
case with the three other pathways.
The exact biologic effect of these differences in pathway activation is
difficult to assess. All of these pathways induce the production of proinflammatory cytokines such as TNF-a, IL-6 and others (109,126,190). NF-KB
binds promoter sites of several pro-inflammatory cytokines resulting in their
production. In addition, NF-KB increases cell survival and proliferation. P38 and
JNK also induce the production of pro-inflammatory cytokines, but they can
induce apoptosis as well as growth and differentiation of the cell. The Erkpathway is proposed to be more involved in control of growth and differentiation
of cells than production of inflammatory cytokines. However, Erk contributes.
significantly to the production of pro-inflammatory cytokines in monocytes
(126,190). Other data suggests that the Erk-pathway is pivotal in the initiation
and also the amount of IL-10 production (99). The regulation of IL-10 is a
complex process and the ability to produce as well as the mechanisms leading to
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IL-10 production varies even among closely related cells such as monocytes,
macrophages and dendritic cells. The available data so far suggest that Erk is a
central regulator of IL-10 production. However, NF-KB is also able to initiate the
production of IL-1 0 but only after stimulation of the TLR-receptor.
Some of the actions are obviously contradictory and the end result of the
pathway activation depends upon complex interactions between different
pathways and also the transcription factors they activate and the genes they
express. These data also suggest that the production of pro-inflammatory
cytokines and therefore the ability to respond to trauma and inflammation is
highly redundant. The knock-out of some of the MAPK-proteins does not result in
reduced production of pro-inflammatory cytokines whereas knock-out mice for
p38 or NF-KB were not viable (191).
Applying this information to our results, the increased and prolonged
activation of NF-KB, p38 and JNK in hypothermia would explain the prolonged
secretion ofTNF-a and IL-6 in our model. The more distinct difference in IL-10
production is more difficult to explain. We believe that the increased activation of
Erk at 15min at 39°C is responsible or contributes significantly to the production
of IL-10. The fact that Erk-activation at 32°C never reaches comparable levels
than at 39°C would fit well into our explanation because Kaiser et al.
demonstrated that the degree of Erk activation correlates with the degree of IL-10
production (192).
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The next step after identification of these significant differences in pathway
activation is to determine if the increased and prolonged activation of the proinflammatory signaling pathways result in differences in gene expression. We
propose that the prolonged activation of NF-KB, p38 and JNK results in a
prolonged production of pro-inflammatory cytokine genes as well as proinflammatory microRNAs. The higher degree of Erk-activation should result in a
high degree of IL-10 gene expression.
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CHAPTER VI
INFLUENCE OF TEMPERATURE ON EXPRESSON OF CYTOKINE GENES
AND MICRORNA - 155

Activated signaling pathways activate transcription factors which initiate
the transcription of genes with the appropriate promoter sequence. The three
different arms of the MAPK-pathway are able to activate several different
transcription factor or different subunits, which then associate with each other in
order to induce gene transcription. NF-KB itself is a transcription factor and
induces gene expression independently without the use of other transcription
factors. In the previous experiment we found a profound impact of temperature
on activation of both the NF-KB and MAPK-pathway. Hypothermia increased and
prolonged the activation of NF-KB, p38 and JNK, whereas the peak activation of
Erk was diminished but still prolonged. Consequently, we determined if these
differences result in increased expression of mRNA of target genes of these
pathways such as TNF-a and IL-10 and if temperature demonstrates the
expected effect.
MicroRNAs are also transcribed like cytokine genes from DNA to RNA and
also depend upon the activation of transcription factors. MiRNA-155 expression
is induced by NF-KB (149,193). Furthermore, the MAPK-pathway has also been
implicated in the induction of miRNA-155 (194-196).
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Therefore, the increased and prolonged activation of both signaling pathways
should also have an effect on the expression of miRNA-155. We hypothesize that
miRNA-155 is increased and has prolonged expression in hypothermia.
Furthermore, a significant effect of temperature on miRNA-155 may also result in
expression changes of the miRNA-155 target, SHIP-1.

RESULTS
Effect of Temperature on Cytokine-Gene Expression
Expression of mRNA precedes the production and secretion of proteins.
Therefore, we chose to investigate earlier time pOints for this experiment than for
the protein secretion. We found that the induction of TNF-a mRNA occured
quickly within 3h after LPS stimulation at both temperatures (Figure 14). The
mRNA-expression of TNF-a peaked at 39°C at 6h with a 22-fold increase
followed by a steep drop to a 2.5 fold increase compared with baseline. Unlike
39°C, TNF-a mRNA expression increased over the whole observation period in
hypothermia reaching comparable levels of fold change.
Our observation show that the induction of IL-1 0 mRNA begins at 3h and
peaks between 12h and 24h in both temperatures (Figure 14). The fold-change
of IL-1 0 mRNA in general was much higher compared to TNF-a, but was again
higher at 39°C than at 32°C. The peak fold change at 39°C was >1100 fold at
12h, whereas 32°C reached 133-fold at the same time. The peak induction in

73

hypothermia appeared to be at 24h. The differences in IL-10 mRNA expression
are significant between the two temperatures at 3h, 6h and 12h.
These changes in mRNA-expression in TNF-a and IL-10 are likely to be
responsible for the observed differences in secreted TNF-a and IL-10. The
prolonged up-regulation of TNF-a mRNA at 12h and 24h results in an increased
production of TNF-a protein at 32°C at 24h and 36h (Figure 11). Conversely, the
strong up-regulation of IL-1 0 mRNA starting at 3h is translated into IL-10 protein
and secreted starting at 6h at 39°C. Although the up-regulation of IL-10 mRNA at
32°C is less pronounced than at 39°C, the difference in secreted IL-10 protein is
much larger than the difference in gene expression would suggest. This
discrepancy may be explained by additional mechanisms such as translational
inhibition or an inhibition of IL-10 protein secretion.

Effect of Temperature on miRNA-155 Expression

The expression of miRNA-155 over time is shown in Figure 15. Similar to
the cytokines, miRNA-155 expression was induced early and a 10-fold upregulation can be observed at 6h in both temperatures. The peak expression in
both temperatures occurred at 12h. MiRNA-155 remains up-regulated on a
higher level, about 20-fold, in hypothermia at 24h and 36h, whereas the
expression decreased to levels below 10-fold at 39°C. The expression difference
at 24h and 36h was significant between 32°C and 39°C.
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Effect of Temperature and miRNA-155 on SHIP-1 Expression
The expression of SHIP-1 is shown in Figure 16. SHIP-1 mRNA is downregulated over the 36h of the study period. At 6h and 12h, SHIP-1 mRNA is
stronger down-regulated at 39°C. At the later time paints, at 24h and 36h, SHIP-1
mRNA remains down-regulated at 32°C the amount of down-regulations
decreases at 39°C. The differences between the two temperatures are significant
at all time paints except at 12h.
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Figure 14: Expression of TNF-a and IL-10 mRNA at 32°C and 39°C
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The induction of TNF-a mRNA was more rapid but less pronounced at 39°C; the
32°C TNF-a mRNA is consistently and increasingly up-regulated within the first

24h. IL-10 mRNA is strongly induced within 3h at 39°C. The IL-10 up-regulation
in hypothermia is delayed but ultimately reaches comparable levels at 24h. Of
note, the degree of IL-10 mRNA up-regulation was high in both temperatures.
* indicates p < 0.05; data are presented as mean ± SEM
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Figure 15: Expression of miRNA-155 at 32°C and 39°C
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Figure 16: Expression of SHIP-1 mRNA at 32°C and 39°C
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SHIP-1 mRNA is initially stronger down-regulation at 39°C followed by an upregulation compared to 3rC. The down-regulation of SHIP-1 allows
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activation of the TLR-pathway leading to an increased secretion of proinflammatory cytokines. These expression changes explain the initially higher
levels of TNF-a and IL-6 at 39°C but also the prolonged and increased secretion
of TNF-a/IL-6 at 32°C. Furthermore, these results are concurrent with the
expression changes of miRNA-155 of which SHIP-1 is

a target. The higher

miRNA-155 levels in hypothermia at 24h and 36h correlate with
suppression of SHIP-1 mRNA at 32°C at these two time pOints.
* indicates p < 0.05; data are presented as mean
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± SEM

a stronger

DISCUSSION
The induction of gene expression is the presumed next step in the
monocyte response to an infection after activation of the signaling pathways.
Gene expression serves several purposes. First, after the secretion of preformed
cytokines during the immediate response, new cytokines have to be produced in
order to replenish the secreted cytokines but also to maintain the communication
between immune cells and orchestration of the immune response. Second, the
inhibition and modulation of the initial pathway activation has to be induced. For
this purpose, phosphatases are induced, which de-phosphorylate the activated
proteins of the TLR-signaling complex such as IRAK-1/2 and TRAF-6. SHIP-1
and SOCS-1 are two such examples of these up-stream inhibitors of the TLRsignaling pathway (119,120,145). In addition, the down-stream signaling
pathways are also inhibited by phosphates. Especially the MAPK-pathway is
highly regulated by inhibitors such as the DUSP's (127-129). Besides the
inhibition of the signaling process, fine-tuned production of inhibitors allows also
the modulation of the response by selective inactivation of one or several arms of
the MAPK-pathway. Lastly, the pathway proteins are also reproduced and the
expression of some of these pathways can change upon cell activation in order
to maintain or diminish the response to the infection.
We investigated the expression of cytokine genes in order to determine if
the reported differences in pathway activation result in differences in gene
expression. We found that TNF-a is increased and has prolonged expression at
32°C; this can be explained by the prolonged activation of the pro-inflammatory
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signaling pathways. Moreover, the sustained up-regulation of TNF-a mRNA at
12h and 24h correlates with the prolonged secretion of TNF-a protein at 24h and
36h. at 39°C, the induction of IL-10 mRNA is stronger and higher than under
hypothermic conditions. We believe that the higher degree of Erk activation is
responsible or contributes strongly to this observation. The IL-10 mRNA upregulation correlates with the high IL-10 levels measured at 39°C. Although the
IL-10 mRNA induction is not as pronounced in hypothermia as at 39°C, there is
still a much stronger up-regulation of IL-10 mRNA (>800-fold) at 32°C compared
to TNF-a (20-fold) indicating inhibition of IL-1 0 protein production and/or
modulation of IL-1 0 protein secretion.
Besides the cytokine mRNA, miRNA-155 is also prolonged expressed in
hypothermia. Since the expression of miRNA-155 is controlled by NF-KB and
probably also by p38 and JNK, the prolonged activation of these pathways is the
likely cause of the increased and prolonged expression of miRNA-155 in
hypothermia. Furthermore, the temperature related differences in miRNA-155
expression may explain the observed increased and prolonged secretion of TNFa protein at 32°C. MiRNA-155 was one of the first microRNAs, which was shown
to respond to inflammatory stimuli (196). Early on, an association with TNF-a was
observed. The causal link between increased miRNA-155 and increased TNF-a
was subsequently demonstrated by several groups (139,145,147). However,
miRNA-155 has also been shown to have anti-inflammatory properties by
inhibiting the expression of MyD88, the central signaling protein of TLR-4, and
TAB2, an important signaling molecule of the NF-KB and MAPK-pathway
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(140,148). While the pro-inflammatory effect of miRNA-155 with an increase in
TNF-a production can be observed within 24h, the suppressive effect on MyD88
requires at least 48h - 72h to be effective. Therefore, the timing of miRNA-155
expression is pivotal in order to determine the biologic effect.
SHIP-1 is one of the main targets by which miRNA-155 increases the
production of pro-inflammatory cytokines (139,145, 197). As expected, SHIP-1
mRNA is strongly down-regulated upon activation of the TLR-pathway. At 6h, the
down-regulation of SHIP-1 is stronger at 39°C correlating with increased
secretion of TNF-a and IL-6; the pro-longed and strong down-regulation of SHIP1 mRNA at 32°C at 24h and 36h explains also the prolonged and increased
levels of TNF-a and IL-6 in hypothermia. Furthermore, the differences in SHIP-1
mRNA between 32°C and 39°C correlate with the expression changes of miRNA155 indicative of a miRNA-155 induced degradation of SHIP-1 mRNA. The
increased expression of miRNA-155 at 32°C lead to the degradation of SHIP-1
mRNA, whereas the decreased levels of miRNA-155 allow up-regulation of
SHIP-1 mRNA at 39°C.
Based on these reports, we propose that the prolonged up-regulation of
miRNA-155 is responsible for the prolonged TNF-a production in hypothermia
(Figure 17).. Increased and prolonged activation of NF-KB, p38 and JNK induces
a strong expression of miRNA-155. The reduced expression of the two TLRpathway inhibitors SHIP-1 and SOCS-1 at 32°C increases pathway activation
and results in prolonged production of TNF-a mRNA, which is then translated into
TNF-a protein and secreted.
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Figure 17: The Increased and Prolonged miRNA-155 Expression Contributes to

the Prolonged and Increased TNF-a-Producti on

Cytoplasm

Nucleus

A prolonged up-regulation of the miRNA-155 results in a reduced expression of
two TLR-4 inhibitors (SHIP-1/S0CS- 1), which in turn increases and prolongs the
activation of the TLR-4 signaling pathway including NF-KB and the MAPKpathway. The increased signaling of the TLR-4 pathway increases the production

of pro-inflammatory cytokines such as TNF-a and IL-6, which then are translated
into cytokine proteins.

82

CHAPTER VII

MiRNA-155 IS RESPONSIBLE FOR THE PROLONGED TNF-a SECRETION
In previous experiments, we found prolonged elevated levels of miRNA155 in hypothermic conditions, which correlated with the prolonged expression of
TNF-a mRNA and protein. Based on available literature we propose that the
increased and prolonged expression of miRNA-155 is responsible for the
sustained TNF-a production at 32°C (Figure 17). Two main targets of miRNA155, SHIP-1 and SOCS-1 are negative regulators of the TLR-4 signaling pathway
(139,145,149). An inhibition of the translation of SHIP-1 and SOCS-1 by miRNA155 increases the signaling of the TLR-4 pathway and results in a prolonged
expression of TNF-a mRNA, which is subsequently translated into TNF-a protein
and secreted. Our results show an expression change of SHIP-1 mRNA
concurrent with an inhibitory effect of miRNA-155 at 32°C at 24h and 36h.
However, miRNA-155 has also been shown to target other proteins such
as MyD88 or TAB2, which results in an anti-inflammatory function for miRNA-155
(140,148). The time course of our data suggests that miRNA-155 has probably
pro-inflammatory functions in our results because the time needed for miRNA155 to develop anti-inflammatory properties is usually more than 24h - 48h. This
can be explained by the targeted proteins: SHIP-1 and SOCS-1, the two proteins
we propose as targets of miRNA-155 in our model, are newly expressed upon
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stimulation of the TLR-4 pathway, whereas MyD88 and TAB2 are already
expressed. MicroRNAs can only inhibit the production of proteins and do not
have any effect on already expressed proteins. Therefore, up-regulation of
miRNA-155 will immediately inhibit the production of SHIP-1 and SOCS-1 and
will also consequently have an immediate effect on the TLR-4 pathway, e.g.
prolong its activation. This is in contrast to MyD88 and TAB2. Both proteins are
pre-existing in the cell and without their presence, the activation of the TLR-4
pathway would be impaired. These pre-existing proteins are not immediately
affected by up-regulation of miRNA-155. However, the re-expression of the
proteins will be affected resulting in a slow decrease of MyD88 and TAB2.
Ultimately, the reduced amount of these two proteins will diminish the signaling
through the TLR-4 pathway. Taken these two actions together, it appears that
miRNA-155 has a dual role; first as a pro-inflammatory microRNA but at the
same time, it acts as a delayed inhibitor of the inflammatory response.
The purpose of the next experiment was to confirm the pro-inflammatory
role of miRNA-155 in our experiments and that the prolonged expression of
miRNA-155 in hypothermia is responsible for the prolonged TNF-a production.
Furthermore, successful modulation of TNF-a secretion by manipulation of
miRNA-155 expression might also offer potential therapeutiC applications. For
this purpose, we modulated the expression of miRNA-155 in the primary
monocytes with microRNA-mimics and microRNA-antagomirs.

84

RESULTS
Over-expression and Suppression of miRNA-155
The transfection of the primary monocytes was successfully
accomplished. Figure 18 shows the miRNA-155 expression levels. The mimics
strongly over-expressed miRNA-155 whereas the antagomirs suppressed
miRNA-155 compared to the with negative control transfected monocytes. In
average, the mimics resulted in a >100-fold up-regulation of miRNA-155 and the
antagomirs reduced the expression about 3-fold. All of these changes were
statistically significant.

Effect of miRNA-155 on TNF-a at 32°C and 39°C
The effect of miRNA-155 on TNF-a is outlined in Figure 19. Independent
of the temperature, over-expression of miRNA-155 resulted in significantly
increased levels of TNF-a. The effect of miRNA-155 up-regulation seems to be
more pronounced at 32°C than at 39°C. Transfection with miRNA-155-mimics at
39°C increased TNF-a to higher levels as in the negative control transfected cells
at 32°C. It is therefore possible to make "39°C look like 32°C".
The suppression of miRNA-155 expression had only a significant effect on
TNF-a levels at 32°C. Suppression of miRNA-155 expression reduced TNF-a to
slightly lower levels than the negative control at 39°C. Thus, suppression of

85

miRNA-155 "makes 32°C look like 39°C". A further knock-down of miRNA-155
expression at 39°C did not translate into significantly lower TNF-o levels.

Effect of miRNA-155 on IL-6
The effects of modulation of the expression of miRNA-155 on IL-6 are
shown in Figure 20. The changes of IL-6 expression changes were similar to the
one observed in TNF-o. The over-expression as well as the suppression of
miRNA-155 in the monocytes in both temperatures had a significant effect on IL6 expression, similarly to the effects observed in TNF-o. In addition, suppression
of miRNA-155 expression had significant effect on IL-6.

Effect of miRNA-155 on IL-10
Manipulation of miRNA-155 expression did not affect the IL-10 levels
consistently (Figure 21). Suppression of miRNA-155 at 39°C reduced IL-10 levels
significantly. However, at 32°C, there was a trend to higher IL-10 levels in the
antagomir-transfected monocytes. However, these effects were not consistent
among the different donors.
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Effect of miRNA-155 on SHIP-1 mRNA
Over-expression of miRNA-155 significantly reduced the expression of
SHIP-1 mRNA whereas suppression of miRNA-155 expression increased SHIP-1
mRNA (Figure 22).
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Figure 18: Successful Over-expression and Suppression of miRNA-155
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Figure 19: E;ffect of miRNA-155 on TNF-a
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Figure 20: Effect of miRNA-155 on IL-6
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Figure 21: Effect of miRNA-155 on IL-10

Effect of MiRNA-155 on Interleukin-10
_

400

_

E 300

---

MiRNA - 155-mimic

C=:I Negative Control

MiRNA - 155 Antagom ir

n=6

*

-1- - - - - - - -

C)

c..
o

200

-j- - - - -I

100

-1- - - -

0....1.....---32C

39C

Only suppression of miRNA- 155 at 39°C had a significant effect on IL-10.
* indicates p < 0.05; data are presented as mean ± SEM

91

Figure 22: Effect of miRNA-155 on SHIP-1 mRNA
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DISCUSSION
MiRNA-155 can have both pro- and anti-inflammatory effects during the
monocyte response depending on the target and the time since the stimulation.
Initially, miRNA-155 has pro-inflammatory properties and increases the activation
of the TLR-4 pathway including the NF-KB and MAPK pathways. This effect is
due to the inhibition of production of SHIP-1 and SOCS-1; both proteins inhibit
the TLR-4 signaling complex upstream. We found expression changes of SHIP-1
mRNA which correlate with an inhibitory effect of miRNA-155 at 24h and 36h. At
a later time point, miRNA-155 reduces the signaling through the TLR-pathway by
inhibition of re-expression of MyD88, the central signaling protein of TLR-4 and
most other TLR's, and reduction of TAB2, a protein, which is an essential cofactor in the activation of TAK1. TAK1 is able to activate both the NF-KB and
MAPK-pathway.
We proposed that TNF-o secretion is prolonged in hypothermia because
of increased and prolonged expression of miRNA-155. We show here that
miRNA-155 is indeed responsible for the prolonged TNF-o secretion. Overexpression of miRNA-155 at 39°C increased TNF-o to slightly higher levels than
those of monocytes transfected with negative controls at 32°C making "39°C look
like 32°C". Of note, over-expression of miRNA-155 in hypothermia increased
TNF-o further. The converse was also found to be true: suppression of miRNA155 at 32°C reduced TNF-o to slightly lower levels than in the negative control of
39°C; thus, making "32°C look like 39°C". Interestingly, a further suppression of
miRNA-155 at 39°C did not translate into significantly lower TNF-o levels, which
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suggests that miRNA-155 is expressed at a very low level and probably inactive.
In summary, modulation of miRNA-155 expression is able to abolish the effects
of temperature on cytokine secretion. We confirmed the pro-inflammatory action
of miRNA-155 by analyzing IL-6 production. Similar to TNF-a, over-expression of
miRNA-155 increased IL-6 in both temperatures, whereas suppression of
miRNA-155 reduced IL-6 expression in both temperatures. In addition, we show
that these effects of miRNA-155 are likely to be mediated by SHIP-1, a well
described target of miRNA-155. Over-expression of miRNA-155 suppresses
SHIP-1 mRNA expression at both temperatures; reduction of miRNA-155
expression with miRNA-155 antagomirs increases the expression of SHIP-1
mRNA. These observations are in line with results of Kurowska-Stelarska et al.
(145).
The effects of miRNA-155 on IL IL-10 are less clear. The effect of miRNA155 manipulation on IL-10 was not consistent. Suppression of miRNA-155 at
39°C reduced IL-10 significantly. In contrast, there was a slight trend for higher
IL-10 levels in miRNA-155 antagomir transfected cells at 32°C. Thus suggesting
that temperature may influence the effect of microRNAs on an additional level
independent of miRNA-155. This result contrasts with the report by KurowskaStelarska et aI., who found that over-expression of miRNA-155 reduces IL-10
(145). The reasons for these differences remain unclear. Both experiments were
conducted with primary human monocytes, which were freshly isolated by the
same technique. In addition, the transfection reagent was also the same; the only
difference was the source of the microRNA mimics, antagomirs and negative
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controls. Further research should be directed to answer this question. We
hypothesize that temperature may influence other pathways which results in
these inconsistent effect of miRNA-155 on IL-10. Alternatively, the production of
other microRNAs, which were not investigated in our research or other
mechanisms directing the production of IL-10, may be strongly affected by
temperature.
In summary, we demonstrate here that miRNA-155 is instrumental in the
prolonged expression of TNF-a and that effect is likely to be mediated by
suppression of SHIP-1. Furthermore, modulation of miRNA-155 expression is
able to reverse the production of pro-inflammatory cytokines. These observations
offer possibilities for therapeutic interventions. However, the effect of changes in
miRNA-155 expression of IL-1 0 secretion and the influence of temperature on
this process warrant further investigations.
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CHAPTER VIII
IL-10 SUPPRESSES MIRNA-155 AND IS AN IMPORTANT NEGATIVE
FEEDBACK LOOP
We have shown in the previous experiment that miRNA-155 is responsible
for the prolonged up-regulation of TNF-a under hypothermic conditions.
However, the regulation of miRNA-155 expression is not entirely elucidated. The
transcription of miRNA-155 is initiated by NF-KB and the MAPK-pathway upon
stimulation of the monocytes with LPS (149,193,194,196). As Figure 15
indicates, there is no difference in miRNA-155 induction between 32°C and 39°C
in the first 12h. After 12h miRNA-155 expression declines at 39°C and remains at
a lower level over the remaining study period. This difference in miRNA-155
could be explained by the prolonged activation of NF-KB, p38 and JNK in
hypothermia. Since the expression is not different in the first 12h, it might as well
be that other factors contribute or are mainly responsible for the observed
difference in miRNA-155 expression after 12h. It has been shown that the
expression of miRNA-155 is not only induced by ligands of the TLR-system but
also by TNF-a (196). This is not surprising considering that the TLR-4 and the
TNF-receptor share several of the intracellular signaling proteins such as IRAK-

1/2 and TRAF-6. Also, the TNF-a receptors utilizes the NF-KB and MAPK
pathway. IL-10 has well described anti-inflammatory properties by suppressing
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the production of TNF-a and other pro-inflammatory cytokines directly (100).
McCoy et al. demonstrated that IL-10 also suppresses

miRNA~155

(198). We

found in our experiment that the difference in IL-10 secretion is one of the most
pronounced differences between 32°C and 39°C, especially at the 12h time point
(Figures 11). Based on the literature and our own data, we hypothesized that IL10 may be the principle regulator of miRNA-155 expression as part of a negative
feedback loop. In this feedback loop, IL-10 would not only reduce the production
of pro-inflammatory cytokines directly, it would also reduce the signaling through
the TLR-pathway by increasing the inhibitors SHIP-1 and SOCS-1 and reduce
the expression of miRNA-155; thereby reinforcing the anti-inflammatory effect.
To delineate the role of IL-10 on miRNA-155 and subsequentlyTNF-a
production we altered IL-10 action in the monocyte culture. For this purpose, we
either added additionallL-10 or blocked the IL-10-Receptor. Adding additionallL10 to the 32°C culture would imitate conditions found at 39°C. Blocking the IL-10receptor at 39°C abolishes the action of IL-1 0 and would imitate conditions found
at 32°C. The demonstration of the biologic relevance of this feedback loop would
indicate that microRNA's are not only regulators of protein production they are
also controlled by proteins. A better understanding of such feedback loops may
allow the targeted modulation of the cell response.
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RESULTS

Addition of IL-1 0 to the Monocyte Culture at 32°C
Addition of IL-10 decreased the TNF-a production significantly at 12h and
24h to half the TNF-a concentration of the untreated 32°C samples (Figure 23).
AdditionallL-10 was also able to suppress the expression of miRNA-155 at 32°C
at 12h and 24h although only the difference at 24h was statistically significant
(Figure 23). We chose to add IL-10 4h after the initial stimulus with LPS because
IL-10 is not produced immediately. The 4h time point was chosen based on
preliminary findings that IL-10 starts rising around 4h.

Blockade of IL-1 O-Receptor at 39°C
Blockade of the IL-1 O-Receptor with a specific antibody to the a subunit of
the IL-1 O-Receptor increased the TNF-a protein levels at 39°C at 12h and 24h
significantly (Figure 24). In line with these results, blockade of the IL-10-Receptor
did increase miRNA-155 expression at 12h and 24h (Figure 24). As with the
addition of IL-1 0 experiment, there was only a statistically significant effect on
miRNA-155 expression at 24h.
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Figure 23: Effect of AdditionallL-10 on TNF-a and miRNA-155 at 32°C
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longer Rh1L-10 was added 4h after initial stimulation with LPS.
* indicates p < 0.05; data are presented as mean
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± SEM

Figure 24: Effect of IL-10 Receptor Blockade on TNF-a and miRNA-155 at 39°C
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Blockade of the IL-10-Recpetor with anti-IL-1O-Recpetor antibodies effectively
blocked the action of IL-10 and increased TNF-a protein secretion and miRNA155 expression at 24h. Comparable to the addition of IL-10 at 32°C, the effect of
the IL-10-Receptor blockade on miRNA-155 takes more time but will probably
also last longer due to the action of miRNA-155.
* indicates p < 0.05; data are presented as mean ± SEM
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DISCUSSION
A tight regulation of the inflammatory response is pivotal for the host in
order to mount an appropriate response to defend the host but also important in
order to prevent excessive damage with potential fatal complications. The
understanding of the various regulatory mechanisms would potentially allow for
targeted interventions. IL-10 is a potent and well described negative regulator of
the immune system (97,98,100). It has been shown that administration of IL-10 in
mice with endotoxemic shock and peritonitis abolishes the shock symptoms and
increases survival (97,98). One of the mechanisms by which IL-10 executes its
anti-inflammatory properties is by blocking the transcription of pro-inflammatory
cytokines such as TNF-o (100). The suppressive effect of IL-10 is not limited to
cytokine genes; IL-10 also reduces the expression of miRNA-155 as we and
Sheedy et al. have shown (198).
We showed here that IL-10, which is the most pronounced
difference between 32°C and 39°C, suppresses miRNA-155, resulting in an
increased expression of SHIP-1 and SOCS-1 and therefore an inhibition of the
TLR-4 signaling pathway, ultimately reducing TNF-o levels at 39°C. We believe
that we have demonstrated the causality of IL-10 by blocking the action of IL-10
at 39°C, which resulted in an increase of miRNA-155 and TNF-o, thus, "making
39°C look like 32°C". The opposite was also shown: administration of IL-10 after
4h of LPS stimulation at 32°C suppressed miRNA-155 and TNF-o. IL-10
administration makes "32°C look like 39°C". We believe that we show here
convincingly that IL-10 is part of an important negative feedback loop in
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regulation of the monocyte response. In this negative feedback loop, IL-10
suppresses miRNA-155 and the reduced expression of this microRNA results in
an increased inhibition of the TLR-4 signaling pathway followed by a subsequent
decrease of TNF-a at 39°C. However, we do not believe that the reduced
miRNA-155 expression is exclusively responsible for the decrease in TNF-a. The
direct suppression of IL-1 0 on the transcription of TNF-a is an important feature
of the negative feedback loop. Our data indicate that reduced expression of
miRNA-155 becomes effective at the 24h time point but has long lasting effects.
The addition of IL-10 as well as the block of the IL-10-Receptor had only effects
on miRNA-155 at 24h, whereas TNF-a was suppressed already at 12h time point
(Figures 23 and 24). These findings suggest that the suppression of miRNA-155
is responsible for long lasting anti-inflammatory effects whereas direct
suppression of TNF-a production is immediately effective.
Based on our results and the available literature, it seems that IL-10 acts
on several levels of the immune response. It reduces the secretion and
production of pro-inflammatory cytokines such as TNF-a but also immunemodulatory cytokines, which enhance phagocytosis and antigen-presenting
capability of macrophages such as IFN-y and GM-CSF. The reduced expression
of pro-inflammatory cytokines reduces the shock symptoms and the acute phase
response. Furthermore, suppression of the antigen presentation reduces the
activation of the adaptive immune system, which also produces pro-inflammatory
cytokines. In addition, IL-10 modifies also microRNA-expression in monocytes.
This action is important because microRNAs have long-lasting effects within the
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cells by modulation of pathways, which will alter the response of the cell when a
subsequent pathogen is encountered. The mechanism, by which IL-10 impairs
the antigen presentation process are not completely elucidated. However, it
would not be surprising, if microRNAs are involved in this process and that these
microRNAs are regulated by IL-10.

In summary, the actions of IL-10 are not limited to one site of action; IL-10
effectively shuts down several pivotal pOints of the immune response: reduction
of pro-inflammatory cytokines, reduced stimulation of cells of the adaptive
immune system and modulation of intracellular signaling pathways by
microRNAs. We propose here that the high levels of IL-1 0 at 39°C contribute
significantly to the reduced expression of miRNA-155 resulting in reduced TNF-a
(Figure 25).
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Figure 25: Proposed Role of IL-10 in Suppression of miRNA-155 Expression and

Subsequent Effect on TNF-a
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IL-10 suppresses TNF-a directly at the 12h time point. In addition, IL-10
suppresses miRNA-155, which increases the production and secretion of TNF-a.
The reduced expression of miRNA-155 would explain the reduced TNF-a
production at 39°C. The lack of IL-10 at 32°C results in sustained miRNA-155
expression and subsequently prolonged TNF-a levels.
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CHAPTER IX
CONCLUSIONS AND OVERVIEW
Hypothermia is a major risk factor for complications and mortality in
elective and emergency surgery. Hypothermic patients are at an increased risk
for wound infections and have a 3-fold higher mortality than non-hypothermic
patients (2). Especially infection associated complications are more frequent in
hypothermic patients but also cardio-vascular complications are increased
(7,31,167).
Previous work has shown that monocytes play an important role in host
defense as the first line by recognizing invading pathogens and orchestrating the
immune response (54,62). It has also been demonstrated that there is prolonged
secretion of pro-inflammatory cytokines and reduced IL-10 production in
hypothermic monocytes (18-21,23,161). The purpose of this project was to
investigate the underlying cellular mechanisms, which may explain these
changes in cytokines secretion. A summary of our results are outlined in Figure
26. We found that hypothermia prolongs the activation of pro-inflammatory
signaling pathways including NF-KB, p38 and JNK. In contrast, Erk, a pathway
which is pivotal for the production of IL-1 0, has increased activation at 39°C.
These changes in pathway activation translate to an increased and prolonged
up-regulation of TNF-a mRNA at 32°C. At 39°C, IL-10 mRNA
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production is highly induced and is translated into IL-10 protein. The IL-10 levels
in the hypothermic monocyte culture are very low. MiRNA-155 is also upregulated in both temperatures, but miRNA-155 decreases at 39°C after 12h,
whereas it remains up-regulated in hypothermia. MiRNA-155 inhibits the
production of two negative regulators of the TLR-4 signaling pathway SHIP-1 and
SOCS-1 (139,145,149). The reduced expression of these two inhibitors prolongs
the activation of the TLR-4 signaling and is responsible for the prolonged
expression of TNF-a at 32°C. The expression changes of SHIP-1 mRNA in both
temperatures correlate well with this proposed role of miRNA-155. We
demonstrate by modulation of miRNA-155 expression with mimics and
antagomirs that miRNA-155 is directly responsible for the prolonged expression
of TNF-a by changing the expression of SHIP-1. The reason for the reduced
miRNA-155 expression at 39°C is the suppressive effect of IL-10. Blockade of
the IL-1 O-Receptor in the 39°C monocyte culture increased both miRNA-155 and
TNF-a, thus supporting the notion that IL-10 provides a pivotal negative feedback
loop in order to limit the production of pro-inflammatory cytokines. Therefore, the
failure of IL-10 production at 32°C results in a sequence of events, which
prolongs the production of pro-inflammatory cytokines such as TNF-a and IL-6
and may ultimately be detrimental to the host.
Animal experiments showed that a prolonged expression of TNF-a leads
to multiple organ failure and death (91,199). We believe that the prolonged
secretion of pro-inflammatory cytokines contributes to the detrimental effects of
hypothermia in surgical patients. Administration of IL-10 abolishes the
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detrimental effects of high levels of pro-inflammatory cytokines as they can be
found in endotoxemic shock or bacterial peritonitis (97,98). It has been shown
that IL-10 suppresses the release and production of TNF-a on the transcription
level (100). We and others demonstrate additionally that IL-10 also suppresses
miRNA-155 (198). Therefore, IL-10 not only suppresses TNF-a production
directly, it also inactivates the pro-inflammatory signaling pathways by increasing
the inhibitors of the TLR-4-pathway, which provides an additional and especially
long-lasting inhibition of the pro-inflammatory response. Thus, IL-10 acts on
several levels and in a sequential manner in order to limit the pro-inflammatory
response.
These results are in line with a common hypothesis of the cause of
multiple organ dysfunction. In his theory, a prolonged inflammatory response
results in a prolonged suppressive counter-inflammatory response, which
subsequently increases the susceptibility of the host organisms to sepsis
(186,187). In this case, our model mimics a systemically exaggerated
inflammatory response. Dampening the increased immune response with
administration of IL-1 0 would reduce the pro-inflammatory response and
therefore also limit the counter-inflammatory response, which may result in an
earlier restoration of immune function and subsequently reducing the risk for
sepsis. Further investigation of this hypothesis should be undertaken by analysis
of miRNA-155 expression or of other pro-inflammatory microRNAs such as
miRNA-101 in blood or serum of patients with sepsis or after trauma. If upregulation of miRNA-155 or another pro-inflammatory microRNA correlates with
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poor outcome, it may be used to monitor immune function but also to guide
immune modulatory treatments of these patients as discussed later.
Alternatively, our results could also mimic local conditions in a surgical
incision or local infection. Hypothermia has been shown to reduce the ability of
neutrophils and monocytes to produce ROS in hypothermia (16,62,200). A
prolonged secretion of pro-inflammatory cytokines may try to compensate for the
failure of neutrophils to kill bacteria by attraction of more leukocytes and
increased stimulation of the present phagocytes. Further investigation of this
theory should focus on miRNA-155 expression in tissue macrophages such as
Langerhans cells or wound healing macrophages. Associations between miRNA155 and other pro-inflammatory micro RNA expression should be correlated with
occurrence of wound infection. An association of miRNA-155 or other proinflammatory microRNA expression with surgical site infection could be used for
risk stratification for infectious complications. In patients with a high risk for
wound infection, additional measures such as prolonged local and systemic
antibiotic treatment may be indicated.
Based on these experiments, miRNA-155 alone or possibly in combination
with other pro-inflammatory microRNAs may be used to monitor the immune
response and to guide immune-modulatory interventions. Patients with sepsis,
after trauma or who are at a high risk for infectious complications may benefit
from a functional evaluation of the immune system as indicated by high or low
expression of pro-infl~mmatory microRNAs such as miRNA-155 followed by
targeted interventions. Patients with high expression of miRNA-155 or other pro108

inflammatory microRNAs may benefit from immune-suppressive treatments
whereas immune-stimulatory medications such as IFN-y or GM-CSF support the
recovery of patients with low miRNA-155 expression. Several clinical trials with
immune-modulatory drugs have been undertaken and all of them failed. IFN-y
was used in trauma patients with the goal to ameliorate post-traumatic immunesuppression. However, there was no difference in outcome between the placebo
and IFN-y group (61, 107). Trials with the goal to reduce the inflammatory
response in sepsis such as the use of anti-TNF-a antibodies failed as well and
even had detrimental outcomes (104-107).One of the reasons for the failure of
immune-modulatory therapy in patients is that it is not possible to functionally
asses the immune system thus far. Treatment of endotoxin shock in animals with
either anti-TNF-a antibodies or IL-10 increases survival whereas immunestimulation in animals with a reduced immune response has been shown to
increase survival (94,95,97,98). However, it is not possible at the moment to
assess the functional state of a patient's immune system and if this particular
patient suffers from an exaggerated immune response, such as in an
endotoxemic shock model, and likely would benefit from an anti-inflammatory or
suffers from immune-suppression possibly benefiting from an immunestimulatory treatment. The first goal therefore should be to identify reliable
markers for the functionality of a patient's immune system and then plan clinical
trials based on the functional assessment of the immune system. MicroRNAs
may provide this information because of their role as central regulators of cell
function. Furthermore, patients receive several therapies such as mechanical
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ventilation, antibiotics, transfusions and many others, all of which may interfere
with an additional immune-modulatory therapy. In addition, it is unlikely that one
additional therapy among so many already used would have a massive impact
on survival or other outcome parameters.
However, if it is possible to stratify the functional status of a patient's
immune system, for example by using miRNA-155 or other pro-inflammatory
microRNAs, targeted interventions, which alter the expression of miRNA-155 or
any of these other microRNAs may be beneficial and improve outcome.
Especially if the microRNA is causally involved in the disease process, such as
miRNA-155, which interacts with the TLR-4 pathway, a therapy directed to alter
the expression of this particular microRNA subsequently influencing the cell
response may be successful. Systemic or local administration of miRNA-155
antagomirs may reduce TNF-a and limit the tissue damage and subsequent
organ dysfunction in patients with an exaggerated immune-response.
Alternatively, administration of IL-10 in patients with high miRNA-155 expression
in blood or serum may also be considered and would also inhibit TNF-a
production directly, but in addition, also suppresses the expression of miRNA155 in circulating monocytes and local macrophages but also other leukocyte
subsets. These two effects act synergistically and may be able to restore the
monocyte function in patients. Immune-modulatory drugs such as IFN-y or GMCSF may influence miRNA-155 expression and subsequently be able to restore
monocyte function and enhance immune function. Furthermore, the effect of
rewarming to 3rC or even hyper-warming to 39°C on the reversibility of the
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TNF-a production should be investigated. Rewarming is the cornerstone of
treatment of hypothermia in patients. If rewarming is not able to reverse the
hypothermia induced changes in monocytes function, other strategies to restore
monocyte function should be investigated.
There are several limitations for this work. Despite our attempts to use a
gentle isolation process, the monocytes may be activated during this process and
the monocyte response may be altered by this prior activation. The majority of
the isolation process was conducted at 3rC. However, some steps have to be
performed at room temperature and expose therefore the monocytes to a
hypothermic environment. Our data indicate that hypothermia profoundly alters
the cell response, especially signaling pathways, resulting in strongly reduced IL10 production at 32°C resulting in prolonged TNF-a production. A potential
contributor for these effects of hypothermia may also be a so far unidentified,
temperature-sensitive protein or channel, which affects the monocyte response
to LPS. Transient receptor potential cation channel subfamily V member 1
(TRPV1) are sensitive to temperature changes and play an important role in
temperature regulation of the body (201,202). TRPV1 channels are also
expressed on immune cells and the knock-out of TRPV1 results in a prolonged
and increased pro-inflammatory response (203,204). Closing of these channels
by hypothermia may contribute to the increased secretion of pro-inflammatory
cytokines in our model. Further research of the role of TRPV1 on the
inflammatory response is warranted.
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In conclusion, we found that hypothermia increases and prolongs TNF-a
and IL-6 production by monocytes. The lack of IL-1 0 secretion under hypothermic
conditions results in a reduced suppression of miRNA-155 expression resulting in
a prolonged and increased TNF-a secretion. We therefore propose that
hypothermia impairs an important feedback loop based on IL-10. The reduced
activation of Erk at 32°C possibly contributes to the lack of IL-10. Further
research should be focused on investigation of additional mechanisms, which are
influenced by hypothermia such as TRPV1 membrane channels. In addition, the
effect of rewarming, the standard therapy for hypothermic patients, on the
reversibility of TNF-a secretion should be examined.
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Figure 26: Summary of Our Results
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APPENDIX: ABBREVIATIONS

General Abbreviations
CARS

Compensatory Anti-inflammatory Response Syndrome

MODS

Multiple Organ Dysfunction Syndrome

SCIP

Surgical Care Improvement Project

SIRS

Systemic Inflammatory Response Syndrome

SSI

Surgical Site Infection

Cell Biology
Ago2

Argonaute 2; cleaves mRNA as part of the RISC

HUVEC

Human Umbilical Vein Endothelial Cell

miRNA

microRNA: short, single stranded RNA

mRNA

messenger RNA: longer, single stranded RNA; serves as template for
protein translation

132

PBMC

Peripheral Blood Mononuclear Cells

PDCD4

Programmed Cell Death Protein 4; target of miRNA-21

RISC

RNA-induced silencing complex

siRNA

silencing RNA

SHIP-1

SH2-domain containing inositol 5' phosphatase 1; target of miRNA155 and inhibitor of the TLR-4 pathway

SOCS-1 Suppressor of Cytokine Signaling 1; target of miRNA-155 and inhibitor
of the TLR-4 and JAKISTAT
THP-1

Human monocytic cell line

TRPV1

Transient receptor potential cation channel subfamily V member 1; a
temperature sensitive plasma membrane channel, which may
contribute to the effects of hypothermia

Immunology

Alarmins Endogenous- proteins, which indicate tissue destruction or danger such
as HSP or HMGB 1
CD14

Cluster of Differentiation 14; marker for monocytes
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CD16

Cluster of Differentiation 16; low affinity Fcy-Receptor Marker for a
subtype of inflammatory monocytes

DAMP

Danger Associated Molecular Pattern; includes Alarmins and PAMPs

GM-CSF Granulocyte-macrophage colony-stimulating factor
HLA-DR Human Leukocyte Antigen DR; subtype of MHC II correlates with
outcome in surgical patients
HMG81

High-Mobility Group Protein 81; an alarmin

HSP

Heat Shock Proteins; serve as alarm ins

IFN-y

Interferon-y; immune stimulatory cytokine

IL-6

Interleukin-6; pro-inflammatory cytokine

IL-10

Interleukin-10; anti-inflammatory cytokine

LPS

Lipopolysaccharide; part of the outer membrane of gram-negative
bacteria; is a DAMP

MHC II

Major Histocompatibility Complex II; expressed on Antigen Presenting
Cells and is necessary for stimulation of T- and 8-cells

NOD

Nucleotide Oligomerization Domain Receptor, a PRR

PAMP

Pathogen Associated Molecular Pattern; bacterial or viral
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Products, which are recognized by the immune system
PRR

Pathogen Recognition Receptor; receptors, which recognizes DAMPs
such as TLR-4 and NODs

RAGE

Receptor for Advanced Glycation End Products, a PRR

ROS

Reactive Oxygen Species; produce by immune cells in order to destroy
bacteria

TLR-4

Toll-Like Receptor 4; well described PRR, which recognizes LPS,
HMGB 1 and HSP

TNF-a

Tumor Necrosis Factor a; pro-inflammatory cytokine

Pathways

ATF-1

Activated Transcription Factor 1; produces pro-inflammatory cytokines

DUSP-1

Dual Specificity Phosphatase 1; target of miRNA-1 01 and
inactivator of p38 and JNK of the MAPK

Erk

Extracellular Signal Related Kinase pathway; part of the MAPK and
important for IL-1 0 production

IKK

Inhibitory Kappa Kinase; activator of NFKB
Beta; inactivates

NFK~
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IK~

Inhibitory kappa protein

IRAK 1 I 2

Interleukin-1 Receptor associated Kinase 1 12; central signaling
protein of the TLR-4 pathway

JNK
MAPK

c-Jun N-terminal Kinase pathway, part of the MAPK pathway
Mitogen Activated Protein Kinases pathway; central stress response
pathway and part of the TLR-4 signaling; consisting of p38, JNK and
Erk

MyD88

Myeloid differentiation primary response gene 88; central signaling
protein of TLR-4

NFKB

Nuclear Factor Kappa Beta; a central stress responsepathway and part
of the TLR-4 signaling; consisting of the p65 and p50 subunits

p38

part of the MAPK pathway

TAB2

TGF-beta activated kinase 1/MAP3K7 binding protein 2; target of
miRNA-155 and part of the MAPK pathway

TAK1

TGF-beta activated kinase 1; part of the MAPK pathway

TRAF6

TNF-Receptor Associated Factor; central signaling protein of the TLR4 pathway
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